<SEC-DOCUMENT>0001811884-23-000021.txt : 20231113
<SEC-HEADER>0001811884-23-000021.hdr.sgml : 20231113
<ACCEPTANCE-DATETIME>20231113104935
ACCESSION NUMBER:		0001811884-23-000021
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231113
DATE AS OF CHANGE:		20231113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		231396342

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20230930.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2022-03-31' xmlns:us-gaap='http://fasb.org/us-gaap/2023' xmlns:srt='http://fasb.org/srt/2023' xmlns:fil='http://www.utahmed.com/20230930' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D230101_230930' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:CurrentFiscalYearEndDate' contextRef='D230101_230930' id='fact2'>--12-31</ix:nonNumeric>
<ix:nonNumeric name='dei:EntityCurrentReportingStatus' contextRef='D230101_230930' id='fact3'>Yes</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D230101_230930' id='fact4'>false</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalYearFocus' contextRef='D230101_230930' id='fact5'>2023</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalPeriodFocus' contextRef='D230101_230930' id='fact6'>Q3</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20230930.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D230101_230930'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E23Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='I231110'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-11-10</i:instant>
</i:period>
</i:context>
<i:context id='E22'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='Y23Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2022-07-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220930'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E21'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-09-30</i:instant>
</i:period>
</i:context>
<i:context id='D230101_230930_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E23Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E23Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E23Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E23Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E23Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id='Y23Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E23Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E23Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E23Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E23Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E22_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='Y22Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-07-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-07-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-07-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-07-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E22Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='D220101_220930_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220930_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220930_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220930_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-Obstetrics'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-Obstetrics_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-Obstetrics_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-Obstetrics'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-Neonatal'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-Neonatal_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-Neonatal_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-Neonatal'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q3_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-07-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-Obstetrics_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-Obstetrics_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-Neonatal_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-Neonatal_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='fil:DistributionRightsAcquisitionAxis'>fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='D230930_DistributionRightsAcquisition-CoopersurgicalInc'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='fil:DistributionRightsAcquisitionAxis'>fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-09-30</i:startDate>
<i:endDate>2023-09-30</i:endDate>
</i:period>
</i:context>
<i:unit id='Pure'>
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:unit id='USD'>
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id='Shares'>
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id='UsdPerShare'>
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
</ix:resources>
</ix:header>
</div>
<div><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>UNITED STATES</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>SECURITIES AND EXCHANGE COMMISSION</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>Washington, D.C. &#160;20549</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><b>FORM </b><ix:nonNumeric name='dei:DocumentType' contextRef='D230101_230930' escape='true'>10-Q</ix:nonNumeric></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentQuarterlyReport' contextRef='D230101_230930' format='ixt-sec:boolballotbox'>&#9746;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the quarterly period ended <ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D230101_230930' format='ixt:datemonthdayyearen'> September 30, 2023</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>OR</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentTransitionReport' contextRef='D230101_230930' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the transition period from  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Commission File No. <span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D230101_230930' escape='true'>001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D230101_230930' escape='true'>UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(Exact name of Registrant as specified in its charter)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D230101_230930' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D230101_230930' escape='true'>87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of incorporation or organization)</p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D230101_230930' escape='true'>7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D230101_230930' escape='true'>Midvale</ix:nonNumeric>, <ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D230101_230930' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric> &#160;<ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D230101_230930' escape='true'>84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>(<ix:nonNumeric name='dei:CityAreaCode' contextRef='D230101_230930' escape='true'>801</ix:nonNumeric>) </span><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D230101_230930' escape='true'>566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0'>Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Title of each class:</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Trading Symbol:</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:Security12bTitle' contextRef='D230101_230930' escape='true'>Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:TradingSymbol' contextRef='D230101_230930' escape='true'>UTMD</ix:nonNumeric></p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:SecurityExchangeName' contextRef='D230101_230930' escape='true'>NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<span style='-sec-ix-hidden:fact3'>Yes</span>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name='dei:EntityInteractiveDataCurrent' contextRef='D230101_230930' escape='true'>Yes</ix:nonNumeric>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Large accelerated filer&#160;<span style='font-family:MS Gothic'>&#9744;</span></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Accelerated filer&#160;<span style='font-family:MS Gothic'>&#9744;</span></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'><ix:nonNumeric name='dei:EntityFilerCategory' contextRef='D230101_230930' format='ixt-sec:entityfilercategoryen'>Non-accelerated filer</ix:nonNumeric> <span style='font-family:MS Gothic'>&#9746;</span></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Smaller reporting company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntitySmallBusiness' contextRef='D230101_230930' format='ixt-sec:boolballotbox'>&#9746;</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Emerging growth company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D230101_230930' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style='font-family:MS Gothic'>&#9744;</span> &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityShellCompany' contextRef='D230101_230930' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9746;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of November 10, 2023: <ix:nonFraction name='dei:EntityCommonStockSharesOutstanding' contextRef='I231110' unitRef='Shares' decimals='INF' scale='0' format='ixt:numdotdecimal'>3,629,525</ix:nonFraction>.&#160;</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<a id='a2'></a><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>INDEX TO FORM 10-Q</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>PAGE</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a3' style='text-decoration:none'>PART I - FINANCIAL INFORMATION</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a3' style='text-decoration:none'>Item 1.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a3' style='text-decoration:none'>Financial Statements</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a4' style='text-decoration:none'>Consolidated Condensed Balance Sheets as of September 30, 2023 and December 31, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a5' style='text-decoration:none'>Consolidated Condensed Statements of Income for the three and nine months ended September 30, 2023 and September 30, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a6' style='text-decoration:none'>Consolidated Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and September 30, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>3</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a7' style='text-decoration:none'>Consolidated Condensed Statements of Stockholders&#8217; Equity for the three and nine months ended September 30, 2023 and September 30, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>4</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a8' style='text-decoration:none'>Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>5</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a9' style='text-decoration:none'>Item 2.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a9' style='text-decoration:none'>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>7</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a10' style='text-decoration:none'>Item 3.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a10' style='text-decoration:none'>Quantitative and Qualitative Disclosures About Market Risk</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>16</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a11' style='text-decoration:none'>Item 4.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a11' style='text-decoration:none'>Controls and Procedures</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>16</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a12' style='text-decoration:none'>PART II &#8211;&#160;OTHER INFORMATION</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a13' style='text-decoration:none'>Item 1.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a13' style='text-decoration:none'>Legal Proceedings</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>17</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a14' style='text-decoration:none'>Item 1A.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a14' style='text-decoration:none'>Risk Factors</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>17</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a15' style='text-decoration:none'>Item 2.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a15' style='text-decoration:none'>Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>18</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a17' style='text-decoration:none'>Item 6.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a17' style='text-decoration:none'>Exhibits</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>18</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a18' style='text-decoration:none'>SIGNATURES</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>19</p>
</td></tr>
</table>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a3'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART I - FINANCIAL INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>Item 1. Financial Statements</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a4'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%;margin-left:4.65pt'><tr style='height:12.75pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style='height:8.25pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>SEPTEMBER 30, 2023 AND DECEMBER 31, 2022</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands)</p>
</td></tr>
<tr style='height:21pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(unaudited)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(audited)</p>
</td></tr>
<tr style='height:19.5pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>SEPTEMBER 30, 2023</span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>DECEMBER 31, 2022</span></p>
</td></tr>
<tr style='height:19.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>ASSETS</span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Current assets:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Cash &amp; investments</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>88,209</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>75,052</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts &amp; other receivables, net</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,487</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,538</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,709</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,814</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other current assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>442</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>515</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>101,847</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>89,919</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Property and equipment, net</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,346</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,224</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Goodwill</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,424</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,354</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>53,042</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>52,755</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets - accumulated amortization</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>47,416</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>42,378</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other intangible assets, net</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,626</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,377</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>131,243</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123,874</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Current liabilities:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>511</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,218</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,666</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,742</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current liabilities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,177</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,960</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Deferred tax liability &#8211; Femcare IIA</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,196</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,514</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Other long term liabilities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,256</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,256</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Operating lease liability</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>305</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>341</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Deferred income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>607</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>549</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,541</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,620</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Stockholders' equity:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Common stock - $<ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E23Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E22' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E22' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>50,000</ix:nonFraction></ix:nonFraction> shares; issued - September 30, 2023, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,629</ix:nonFraction></ix:nonFraction> shares and December 31, 2022, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E22' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E22' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accumulated other comprehensive income (loss)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E23Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,999</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E22' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,039</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Additional paid-in capital</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>521</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>251</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Retained earnings</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>135,144</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>126,006</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total stockholders' equity</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123,702</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>114,254</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities and stockholders' equity</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>131,243</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123,874</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>1</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a5'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%;margin-left:4.65pt'><tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND SEPTEMBER 30, 2022</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Three Months Ended </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Nine Months Ended </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2023</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2022</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2023</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2022</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Sales, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,505</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,955</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37,891</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>38,707</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cost of goods sold</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,146</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,769</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,951</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,838</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Gross profit</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,359</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,186</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>22,940</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>23,869</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating expense</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Selling, general and administrative</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,252</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,933</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,693</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,779</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Research &amp; development</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>138</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>112</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>414</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>370</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total operating expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,390</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,045</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,107</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,149</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Operating income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,969</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,141</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,833</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,720</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>812</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>198</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,239</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>348</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Income before provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,781</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,339</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>15,072</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>15,068</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>846</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,059</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,723</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,150</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,935</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,280</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,349</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,918</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (basic)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y23Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.08</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y22Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.18</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D230101_230930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.40</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D220101_220930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.27</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (diluted)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160; &#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y23Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.08</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160; &#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y22Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.18</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D230101_230930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.39</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D220101_220930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.26</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding - basic</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,629</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y22Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,625</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D230101_230930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,629</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D220101_220930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,641</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding - diluted</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,639</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y22Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,634</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D230101_230930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,638</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D220101_220930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,650</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other comprehensive income (loss):</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:23.25pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Foreign currency translation net of taxes of $<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y23Q3' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y22Q3' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='D230101_230930' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='D220101_220930' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'>0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,012</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,572</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,377</ix:nonFraction>)</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total comprehensive income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,923</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,708</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,390</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,541</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:38.9pt'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>2</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a6'></a><table style='border-collapse:collapse;width:100%;margin-left:4.3pt'><tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND SEPTEMBER 30, 2022</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Nine Months Ended<br/>September 30,</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2023</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,349</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,918</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Depreciation</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>465</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>454</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AmortizationOfIntangibleAssets' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,824</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AmortizationOfIntangibleAssets' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,837</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Provision for (recovery of) losses on accounts receivable</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>(<ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>31</ix:nonFraction>)</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21</ix:nonFraction></span></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization of right-of-use assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>39</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>39</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Deferred income taxes</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>284</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='D220101_220930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>409</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Stock-based compensation expense</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>153</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Tax benefit attributable to exercise of stock options</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='D220101_220930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Changes in operating assets and liabilities:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts receivable and other receivables</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,133</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,059</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>925</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,065</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Prepaid expenses and other current assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>19</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>712</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>540</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,093</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,075</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total adjustments</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,600</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,549</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash provided by operating activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>16,949</ix:nonFraction></span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>15,467</ix:nonFraction></span></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Capital expenditures for:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Property and equipment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>549</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>771</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Intangible assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PaymentsToAcquireIntangibleAssets' contextRef='D230101_230930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquireIntangibleAssets' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash used in investing activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>549</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='D220101_220930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>780</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Proceeds from issuance of common stock - options</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>117</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Common stock purchased and retired</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PaymentsForRepurchaseOfCommonStock' contextRef='D230101_230930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsForRepurchaseOfCommonStock' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,495</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Payment of dividends</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,211</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,112</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash used in financing activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,094</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='D220101_220930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,564</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Effect of exchange rate changes on cash</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='D230101_230930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>149</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='D220101_220930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,586</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net increase in cash and cash equivalents</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,157</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,537</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cash at beginning of period</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>75,052</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>60,974</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cash at end of period</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>88,209</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>69,511</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td colspan='2' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,489</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,502</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for interest</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='D230101_230930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='D220101_220930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>3</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a7'></a><table style='border-collapse:collapse;width:100%'><tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1095.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1095.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1095.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND SEPTEMBER 30, 2022</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1095.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(In thousands - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Accumulated</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Additional</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Other</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='bottom' style='width:222.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Common Stock</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Paid-in</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Comprehensive</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Retained</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Stockholders'</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:180.2pt;padding-right:5.75pt'></td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Shares</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Amount</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Capital</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Income</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Earnings</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Equity</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at June 30, 2023</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E23Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,629</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>432</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q2_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,986</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>132,279</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121,762</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>53</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>53</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,012</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> (<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,012</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,071</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,071</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,935</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,935</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2023</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E23Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,630</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>521</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,999</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>135,144</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123,702</ix:nonFraction></p>
</td></tr>
<tr style='height:25.5pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2022 </p>
</td><td valign='middle' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction> </p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>251</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,039</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>126,006</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>114,254</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>2</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D230101_230930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>117</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D230101_230930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D230101_230930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>117</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D230101_230930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>153</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D230101_230930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D230101_230930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>153</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D230101_230930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D230101_230930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D230101_230930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D230101_230930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D230101_230930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D230101_230930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,212</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,212</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,349</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,349</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2023</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E23Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,630</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>521</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,999</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>135,144</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123,702</ix:nonFraction></p>
</td></tr>
<tr style='height:25.5pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at June 30, 2022</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,625</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,858</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>119,293</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,471</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>20</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>20</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>38</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>38</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,572</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> (<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,572</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,051</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,051</ix:nonFraction>)</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,280</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,280</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2022</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,625</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>58</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,431</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>122,521</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>108,185</ix:nonFraction></p>
</td></tr>
<tr style='height:25.2pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.7pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2021 </p>
</td><td valign='middle' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E21_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction> </p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>841</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,054</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115,314</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,138</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D220101_220930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D220101_220930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D220101_220930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D220101_220930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D220101_220930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D220101_220930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock purchased and retired</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodShares' contextRef='D220101_220930_StEqComps-CommonStock' sign='-' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>30</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D220101_220930_StEqComps-CommonStock' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D220101_220930_StEqComps-AddPaidInCap' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>947</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D220101_220930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D220101_220930_StEqComps-RetainedEarnings' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,548</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D220101_220930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,495</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220930_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,377</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,377</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D220101_220930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D220101_220930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D220101_220930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,162</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,162</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:92.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:112.05pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:137.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:197.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:120.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,918</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:169.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,918</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2022</p>
</td><td valign='middle' style='width:92.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,625</ix:nonFraction></p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:112.05pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:137.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>58</ix:nonFraction></p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:197.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,431</ix:nonFraction>)</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:120.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>122,521</ix:nonFraction></p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:169.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>108,185</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='width:180.2pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='middle' style='width:92.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:112.05pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:137.6pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:197.15pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:120.55pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:169.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.75pt'><td valign='bottom' style='width:180.2pt;padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='middle' style='width:92.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:112.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:137.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:197.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:120.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:17.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:169.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>4</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a8'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(unaudited)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. (&quot;UTMD&quot; or &quot;the Company&quot;) annual report on Form 10-K for the year ended December 31, 2022. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
</ix:nonNumeric><p style='font:10pt CG Times;margin:0'>&#160;</p>
 <ix:nonNumeric name='us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(2) Recent Accounting Standards. </p>
 <ix:nonNumeric name='us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
 <ix:nonNumeric name='us-gaap:InventoryDisclosureTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>(3) Inventories at September 30, 2023, and December 31, 2022, consisted of the following:</p>
<ix:nonNumeric name='us-gaap:ScheduleOfInventoryCurrentTableTextBlock' contextRef='D230101_230930' escape='true'><table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:411.4pt'></td><td valign='top' style='width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'> September 30, 2023</p>
</td><td valign='top' style='width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>December 31, 2022</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Finished goods</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,338</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,896</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Work-in-process</p>
</td><td valign='top' style='width:31.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:308.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,654</ix:nonFraction></p>
</td><td valign='top' style='width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:31.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:288.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,193</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Raw materials</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,717</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,725</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total</p>
</td><td valign='top' style='width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,709</ix:nonFraction></p>
</td><td valign='top' style='width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,814</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(4) Stock-Based Compensation. At September 30, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2023, and 2022, the Company recognized $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>53</ix:nonFraction> and $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>38</ix:nonFraction>, respectively, in stock based compensation cost. &#160;In the nine months ended September 30, 2023, and 2022, the Company recognized $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>153</ix:nonFraction> and $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction>, respectively, in stock based compensation cost.</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ProductWarrantyDisclosureTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, <ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E22' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'><ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E23Q3' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'>no</ix:nonFraction></ix:nonFraction> warranty reserve was made at December 31, 2022, or September 30, 2023. </p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:RevenueRecognitionPolicyTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(6) Global 3Q 2023 revenues (USD) by product category:</p>
<ix:nonNumeric name='fil:ScheduleOfRevenuesByProductCategoryTextBlock' contextRef='D230101_230930' escape='true'><table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:180pt'></td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Domestic</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Outside US</p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Labor &amp; Delivery</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-Obstetrics_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,066</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-Obstetrics_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>357</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-Obstetrics' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,423</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,600</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,772</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,372</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-Neonatal_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,363</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-Neonatal_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>521</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-Neonatal' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,884</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,236</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,590</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,826</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,265</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,240</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,505</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global 9M 2023 revenues (USD) by product category:</p>
<table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:180pt'></td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Domestic</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Outside US</p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Labor &amp; Delivery</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-Obstetrics_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,725</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-Obstetrics_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>788</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-Obstetrics' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,513</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,805</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,076</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>16,881</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-Neonatal_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,892</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-Neonatal_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,150</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-Neonatal' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,042</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,045</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,410</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,455</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,467</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>16,424</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37,891</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>5</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/> <ix:nonNumeric name='us-gaap:IntangibleAssetsDisclosureTextBlock' contextRef='D230101_230930' escape='true'><p style='font:12pt Times New Roman;margin:0;color:#000000'><span style='font-size:10pt'>(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) as of February 1, 2019. The $<ix:nonFraction name='us-gaap:FinitelivedIntangibleAssetsAcquired1' contextRef='Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,000</ix:nonFraction> purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over a remaining <ix:nonFraction name='fil:RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' contextRef='D230930_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='Pure' decimals='0' format='ixt-sec:numwordsen'>one</ix:nonFraction> month of life as of September 30, 2023 of the prior CSI distribution agreement with Femcare Ltd.</span></p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<span style='font-family:Times New Roman;color:#000000'> </span><ix:nonNumeric name='us-gaap:EarningsPerShareTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3rd quarter 2023.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0'> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:12.5pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>(<i>in thousands</i>)</p>
</td><td colspan='3' valign='top' style='width:337.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Three months ended</p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td colspan='3' valign='top' style='width:391.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Nine months ended</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='top' style='width:337.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30,</p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td colspan='3' valign='top' style='width:391.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30,</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'></td><td valign='middle' style='width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2023</p>
</td><td valign='top' style='width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2023</p>
</td><td valign='top' style='width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><b>Numerator</b></p>
</td><td valign='top' style='background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.2pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='middle' style='width:136.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,935</ix:nonFraction></p>
</td><td valign='top' style='width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:161.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,280</ix:nonFraction></p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:184.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D230101_230930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,349</ix:nonFraction></p>
</td><td valign='top' style='width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:172.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,918</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:12pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><b>Denominator</b></p>
</td><td valign='top' style='width:136.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:161.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:184.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:172.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Weighted average shares, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,629</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y22Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,625</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D230101_230930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,629</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D220101_220930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,641</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Dilutive effect of stock options</p>
</td><td valign='middle' style='width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>10</ix:nonFraction></p>
</td><td valign='top' style='width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y22Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>9</ix:nonFraction></p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='D230101_230930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>9</ix:nonFraction></p>
</td><td valign='top' style='width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='D220101_220930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>9</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Diluted shares</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y23Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,639</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y22Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,634</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D230101_230930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,638</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D220101_220930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,650</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='middle' style='width:136.85pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:161.1pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:184.2pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:172.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y23Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.08</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y22Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.18</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D230101_230930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.40</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D220101_220930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.27</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:321.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, diluted</p>
</td><td valign='middle' style='width:136.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y23Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.08</ix:nonFraction></p>
</td><td valign='top' style='width:39.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:161.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y22Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.18</ix:nonFraction></p>
</td><td valign='top' style='width:45.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:184.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D230101_230930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.39</ix:nonFraction></p>
</td><td valign='top' style='width:34.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:172.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D220101_220930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.26</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
 <ix:nonNumeric name='us-gaap:SubsequentEventsTextBlock' contextRef='D230101_230930' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
</ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>6</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a9'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>General</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2022, provided a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; A$ or AUD = Australia Dollars; &#163; or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Analysis of Results of Operations</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>a)</kbd><kbd style='margin-left:24.3pt'></kbd>Overview &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Income statement results in 3Q and 9M 2023 compared to the same periods of 2022 were as follows:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:195.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:87.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023</span></p>
</td><td valign='top' style='width:84.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>change</span></p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023</span></p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td><td valign='top' style='width:78.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:195.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net Sales</p>
</td><td valign='top' style='background-color:#CCEEFF;width:87.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,505</p>
</td><td valign='top' style='background-color:#CCEEFF;width:84.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,955</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(3.5%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:82.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 37,891</p>
</td><td valign='top' style='background-color:#CCEEFF;width:82.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 38,707</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(2.1%)</p>
</td></tr>
<tr><td valign='top' style='width:195.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gross Profit</p>
</td><td valign='top' style='width:87.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,359</p>
</td><td valign='top' style='width:84.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8,186</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(10.1%)</p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>22,940</p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23,869</p>
</td><td valign='top' style='width:78.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(3.9%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:195.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating Income</p>
</td><td valign='top' style='background-color:#CCEEFF;width:87.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,969</p>
</td><td valign='top' style='background-color:#CCEEFF;width:84.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,141</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(22.8%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:82.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12,833</p>
</td><td valign='top' style='background-color:#CCEEFF;width:82.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>14,720</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(12.8%)</p>
</td></tr>
<tr><td valign='top' style='width:195.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Income Before Tax</p>
</td><td valign='top' style='width:87.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,781</p>
</td><td valign='top' style='width:84.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,339</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(10.5%)</p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>15,072</p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>15,068</p>
</td><td valign='top' style='width:78.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:195.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net Income (NI)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:87.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,935</p>
</td><td valign='top' style='background-color:#CCEEFF;width:84.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,280</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(8.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:82.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12,349</p>
</td><td valign='top' style='background-color:#CCEEFF;width:82.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>11,918</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.6%</p>
</td></tr>
<tr><td valign='top' style='width:195.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per Diluted Share (EPS)</p>
</td><td valign='top' style='width:87.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1.081</p>
</td><td valign='top' style='width:84.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1.178</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(8.2%)</p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.394</p>
</td><td valign='top' style='width:82.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.265</p>
</td><td valign='top' style='width:78.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4.0%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Worldwide (WW) consolidated sales in 3Q 2023 were $450 lower than in 3Q 2022, and were $816 lower in 9M 2023 compared to 9M 2022. &#160;This essentially was because 3Q 2023 biopharmaceutical OEM sales were $1,217 lower than in 3Q 2022, and were $1,847 lower in 9M 2023 compared to 9M 2022. &#160;Sales invoiced in foreign currencies, which did not include any biopharmaceutical OEM sales, represented 25% of total WW consolidated 3Q 2023 sales (when expressed in USD) and 29% of 9M 2023 total WW consolidated sales. Constant currency sales, U.S. dollar sales using the same foreign currency exchange (FX) rates as in the prior year&#8217;s same periods, were $155 higher in 3Q 2023 as a result of a stronger EUR and GBP compared to 3Q 2022, but $33 lower for 9M 2023 because of a weaker AUS and CAD, despite a stronger EUR, for 9M 2023 year-to-date.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Profit margins in 3Q and 9M 2023 compared to 3Q and 9M 2022 follow: </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:269.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:110pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'>3Q 2023</p>
</td><td valign='top' style='width:105.85pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3Q 2022</p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9M 2023</p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9M 2022</p>
</td></tr>
<tr><td valign='top' style='width:269.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:110pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'><span style='border-bottom:1px solid #000000'>(Jul &#8211;&#160;Sep)</span></p>
</td><td valign='top' style='width:105.85pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>(Jul &#8211;&#160;Sep)</span></p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>(Jan &#8211;&#160;Sep)</span></p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>(Jan &#8211;&#160;Sep)</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:269.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (GP/ sales):</p>
</td><td valign='top' style='background-color:#CCEEFF;width:110pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>58.8%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>63.2%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:102.85pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>60.5%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:102.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>61.7%</p>
</td></tr>
<tr><td valign='top' style='width:269.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (OI/ sales):</p>
</td><td valign='top' style='width:110pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>31.7%</p>
</td><td valign='top' style='width:105.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>39.7%</p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>33.9%</p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>38.0%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:269.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>EBT Margin (EBT/ sales):</p>
</td><td valign='top' style='background-color:#CCEEFF;width:110pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>38.2%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>41.2%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:102.85pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>39.8%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:102.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>38.9%</p>
</td></tr>
<tr><td valign='top' style='width:269.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin (NI/ sales):</p>
</td><td valign='top' style='width:110pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>31.5%</p>
</td><td valign='top' style='width:105.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>33.0%</p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>32.6%</p>
</td><td valign='top' style='width:102.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>30.8%</p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:690.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>EBT = Income Before Taxes = (Operating Income + Non-Operating Income)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 9M 2023, UTMD achieved its targeted GP margin (GPM), although somewhat lower than in 9M 2022 due to planned higher manufacturing overhead costs with less absorption because of lower sales. &#160;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. The lower 3Q 2023 GPM was a good example of this. In addition to the lower absorption of higher overhead costs, the Company had an unfavorable product mix due to much higher foreign distributor sales compared to 3Q 2022, and experienced higher than normal medical expenses in its self-funded U.S. health care plan. &#160;International distributor prices are lower than prices of products sold directly to medical facilities WW. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In addition to the 4.4 percentage-point lower 3Q 2023 GPM and the 1.2 percentage-point lower 9M 2023 GPM, the Operating Income margins in both periods were reduced another 2.8 percentage points by 2023 litigation expenses captured in General &amp; Administrative (G&amp;A) expenses. The Operating Income margins are Operating Income in the applicable time period divided by sales in the same period. Due primarily to interest earned on cash balances which are included in Non-operating income, UTMD was able to achieve higher Income Before Tax, Net Income and Earnings per Diluted Share in 9M 2023 compared to 9M 2022.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>7</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s September 30, 2023 Balance Sheet, in the absence of debt, continued to strengthen with total assets up $0.8 million from the end of 2022. Ending Cash and Investments were $88.2 million on September 30, 2023 compared to $75.1 million on December 31, 2022, after paying $3.2 million in cash dividends to stockholders and purchasing $0.5 million in new Property and Equipment in 9M 2023. &#160;UTMD&#8217;s cash balance increased $3.62/ outstanding share at September 30, 2023 from the end of 2022 with a 4% increase in Net Income, while the stock price declined $14.53/ share. Stockholders&#8217; Equity (SE) increased $9.4 million in the nine-month period from December 31, 2022 despite the fact that $3.2 million in dividends reduced SE.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 3Q 2023 compared to the end of calendar year 2022 and the end of 3Q 2022 follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.25pt'><td valign='top' style='width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>9-30-23</span></p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>12-31-22</span></p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>9-30-22</span></p>
</td><td valign='top' style='width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr style='height:11.25pt'><td valign='top' style='background-color:#CCEEFF;width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.22134</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.20771</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>1.1%</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.11303</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center'>9.7%</p>
</td></tr>
<tr style='height:11.25pt'><td valign='top' style='width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.05841</p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.06940</p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>(1.0%)</span></p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.97878</p>
</td><td valign='top' style='width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center'>8.1%</p>
</td></tr>
<tr style='height:11.25pt'><td valign='top' style='background-color:#CCEEFF;width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.64494</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.68050</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>(5.2%)</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.64366</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center'>0.2%</p>
</td></tr>
<tr style='height:11.25pt'><td valign='top' style='width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.73873</p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.73899</p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>-</span></p>
</td><td valign='top' style='width:115.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.72722</p>
</td><td valign='top' style='width:114.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center'>1.6%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>b)</kbd><kbd style='margin-left:22.5pt'></kbd>Revenues (sales)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. &#160;For the U.S., Ireland, UK, France, Canada, Australia and New Zealand, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale. About 14% of UTMD&#8217;s domestic end user sales, excluding Filshie device sales, go through third party med/surg distributors which contract separately with clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility. &#160;UTMD&#8217;s T&amp;C of Sale to end user facilities are substantially the same for customers in the U.S. and outside the U.S. (OUS).</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year or less. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Total WW UTMD consolidated <b>3Q 2023</b> sales were $450 (3.0%) lower than in 3Q 2022. WW constant currency sales were $605 (4.7%) lower. U.S. domestic sales were 15.7% lower (obviously without any FX impact), and outside the U.S. (OUS) sales were 20.8% higher. Without the benefit of a weaker USD in converting foreign currency sales, 3Q 2023 OUS sales were 17.2% higher. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Domestic U.S. sales in 3Q 2023 were $7,265 compared to $8,615 in 3Q 2022. &#160;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and acquisition history. Domestic direct other device sales, representing 56% of total domestic sales, were $9 (+0.2%) higher in 3Q 2023 than in 3Q 2022. Domestic OEM sales, representing 28% of total domestic sales, were $1,019 (33.4%) lower, including $1,103 lower U.S. biopharmaceutical OEM sales. Direct Filshie device sales, representing 16% of total domestic sales, were $341 (23.0%) lower in 3Q 2023 compared to 3Q 2022.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>8</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>OUS sales in 3Q 2023 were 20.8% higher at $5,240 compared to $4,340 in 3Q 2022. The increase in USD-denominated OUS sales was leveraged as a result of a weaker USD relative to the EUR and GBP, which added $155 to OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies in constant currency terms. FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 3Q 2023 and 3Q 2022 for revenue purposes follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:171.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>3Q 2023</span></p>
</td><td valign='top' style='width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:175.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2669</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.1760</p>
</td><td valign='top' style='background-color:#CCEEFF;width:175.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+7.7%</p>
</td></tr>
<tr><td valign='top' style='width:171.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.0711</p>
</td><td valign='top' style='width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.0040</p>
</td><td valign='top' style='width:175.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+6.7%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.6572</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.6828</p>
</td><td valign='top' style='background-color:#CCEEFF;width:175.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(3.7%)</p>
</td></tr>
<tr><td valign='top' style='width:171.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7462</p>
</td><td valign='top' style='width:171.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7663</p>
</td><td valign='top' style='width:175.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(2.6%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The weighted average favorable FX rate difference impact on 3Q 2023 foreign currency OUS sales was 5.2%, increasing reported USD sales by $155 relative to the same foreign currency sales in 3Q 2022. &#160;In constant currency terms, foreign currency sales in 3Q 2023 were 17.2% higher than in 3Q 2022. The portion of OUS sales invoiced in foreign currencies in USD terms were 25.0% of total consolidated 3Q 2023 sales compared to 19.3% in 3Q 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &#160;Export sales from the U.S. to OUS distributors are invoiced in USD. &#160;Direct to end-user foreign currency OUS 3Q 2023 sales in USD terms were 19.6% higher in Ireland, 21.6% lower in Canada, 8.2% higher in France, 30.8% lower in AUS/NZ and 17.2% higher in the UK than in 3Q 2022. Sales to OUS distributors/ international OEM (including biopharmaceutical) customers were 35.5% higher in 3Q 2023 than in 3Q 2022. Total consolidated 9M 2023 UTMD WW consolidated sales were $816 (2.1%) lower than in 9M 2022. Constant currency 9M 2023 sales were $33 (+0.1%) lower due to a slightly stronger USD year-to-date. U.S. domestic sales were 12.1% lower and OUS sales were 15.0% higher. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Domestic U.S. sales in <b>9M 2023</b> were $21,467 compared to $24,429 in 9M 2022. &#160;Direct other device sales, representing 53% of total domestic sales, were $689 (5.7%) lower in 9M 2023 than in 9M 2022. &#160;The lower direct other device sales year-to-date resulted from continued supply chain disruption. Domestic OEM sales, representing 30% of total domestic sales, were $1,919 (22.8%) lower. The biopharmaceutical portion of domestic OEM sales were $1,963 (28.2%) lower. &#160;Direct domestic Filshie device sales, representing 17% of total domestic sales, were $354 (9.0%) lower in 9M 2023 compared to 9M 2022 due to lower demand. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS sales in 9M 2023 were 15.0% higher at $16,424 compared to $14,278 in 9M 2022. The increase in 9M 2023 USD-denominated OUS sales was only slightly diminished as a result of a stronger USD which subtracted $33 from OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies (in constant currency terms). &#160;FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 9M 2023 and 9M 2022 for revenue purposes follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:171.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>9M 2023</span></p>
</td><td valign='top' style='width:171.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td><td valign='top' style='width:176.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2434</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2488</p>
</td><td valign='top' style='background-color:#CCEEFF;width:176.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(0.4%)</p>
</td></tr>
<tr><td valign='top' style='width:171.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.0790</p>
</td><td valign='top' style='width:171.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.0672</p>
</td><td valign='top' style='width:176.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+1.1%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.6708</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7058</p>
</td><td valign='top' style='background-color:#CCEEFF;width:176.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(5.0%)</p>
</td></tr>
<tr><td valign='top' style='width:171.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7432</p>
</td><td valign='top' style='width:171.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7797</p>
</td><td valign='top' style='width:176.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(4.7%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>The weighted-average unfavorable impact on 9M 2023 foreign currency OUS sales was just 0.3%, reducing reported USD sales by $33 relative to the same foreign currency sales in 9M 2022. &#160;In constant currency terms, OUS sales in 9M 2023 were 15.3% higher than in 9M 2022. The portion of OUS sales invoiced in foreign currencies in USD terms was 28.8% of total consolidated 9M 2023 sales compared to 23.9% in 9M 2022. Direct to end-user foreign currency OUS 9M 2023 sales in USD terms were 5.3% higher in Ireland, 14.1% lower in Canada, 9.5% higher in France, 21.7% higher in the UK and 18.2% lower in AUS/NZ. Sales to OUS distributors/OEM (including biopharmaceutical) customers were 21.2% higher in 9M 2023 than in 9M 2022.</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Since shipments to OEM customers and OUS distributors typically have long lead times, the current order backlog added to 9M 2023 sales results for those segments provides a fair estimate for 2023 sales as a whole, barring new unresolved raw material supply constraints and further third-party sterilization capacity limits. Based on the current backlog, management expects that WW biopharmaceutical OEM sales to its largest customer will be about $3 million lower in 2023 than in 2022, representing about 17% of 2023 total consolidated sales compared to 22% in 2022. &#160;This projection is consistent with management&#8217;s beginning of year 2023 sales estimates, and suggests a net total annual 2023 consolidated sales decline of about $2 million. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>UTMD segments sales into the following general product categories: &#160;gynecology/ electrosurgery, labor &amp; delivery, neonatal critical care, and miscellaneous including blood pressure monitoring kits and accessories as well as related OEM products.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>In 3Q 2023 compared to 3Q 2022, WW gynecology/ electrosurgery sales were 6% lower, WW neonatal device sales were 3% higher, WW labor &amp; delivery device sales were 12% higher and WW blood pressure monitoring and related OEM product sales were 8% lower. &#160;In 9M 2023 compared to 9M 2022, WW gynecology/ electrosurgery device sales were 4% higher, WW labor &amp; delivery device sales were about the same, WW neonatal device sales were 10% lower and WW blood pressure monitoring and related OEM product sales were 7% lower.</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The following table provides USD sales amounts divided into general product categories for total sales and the subset of OUS sales:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global 3Q 2023 revenues (USD) by product category:</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:583.25pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Domestic</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Outside US</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Total</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Labor &amp; Delivery</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;1,066</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;357</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;1,423</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>2,600</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>2,772</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>5,372</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,363</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>521</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,884</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Blood Pressure Monitoring and Accessories*</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>2,236</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>1,590</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>3,826</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;7,265</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;5,240</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,505</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global 9M 2023 revenues (USD) by product category:</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:583.25pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Domestic</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Outside US</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Total</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Labor &amp; Delivery</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;2,725</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;788</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;3,513</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>7,805</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>9,076</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>16,881</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,892</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,150</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,042</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Blood Pressure Monitoring and Accessories*</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>7,045</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>5,410</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>12,455</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 21,467</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 16,424</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 37,891</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:24.3pt'></kbd>*includes molded components sold to OEM customers.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'> &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>9</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>c)</kbd><kbd style='margin-left:22.5pt'></kbd>Gross Profit&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Gross Profit results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers from revenues. UTMD&#8217;s Gross Profit was $827 (10.1%) lower in 3Q 2023 than in 3Q 2022, and $929 (3.9%) lower in 9M 2023 than in 9M 2022. UTMD price increases to customers since early 2022 were substantially lower than its continued cost increases, with continued &#8220;sticky&#8221; inflation. &#160;Although direct labor productivity in 3Q 2023 remained consistent with the past, raw material costs continued to increase and higher manufacturing overhead costs were less absorbed by lower revenues. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>About half of the 4.4 percentage-point lower Gross Profit margin (GPM) in 3Q 2023 compared to 3Q 2022 was due to $1,039 (+52%) higher sales to OUS distributors.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>d)</kbd><kbd style='margin-left:22.5pt'></kbd>Operating Income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Operating Income results from subtracting Operating Expenses from Gross Profit. &#160;Operating Income in 3Q 2023 was $3,969 compared to $5,141 in 3Q 2022, a $1,171 (22.8%) decline; and was $12,833 in 9M 2023 compared to $14,720 in 9M 2022, a $1,887 (12.8%) decline. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Operating Expenses are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. The following table summarizes Operating Expenses in 3Q and 9M 2023 compared to the same periods in 2022 by Operating Expense (OE) category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:218.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>OE Category</span></p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023</span></p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:54.25pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.7pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023</span></p>
</td><td valign='top' style='width:63.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.7pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td><td valign='top' style='width:63.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:218.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>S&amp;M:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;417</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.3</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;373</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.25pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2.9</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.7pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,209</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.7pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,066</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2.7</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:218.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>G&amp;A:</p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,835</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>22.7</p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,560</p>
</td><td valign='top' style='width:54.25pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.8</p>
</td><td valign='top' style='width:63.7pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8,484</p>
</td><td valign='top' style='width:63.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>22.4</p>
</td><td valign='top' style='width:63.7pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,713</p>
</td><td valign='top' style='width:63.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.9</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:218.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>R&amp;D:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>138</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1.1</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>112</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.25pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>0.8</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.7pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>414</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1.1</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.7pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>370</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1.0</span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:218.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total OE:</p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,390</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>27.1</p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,045</p>
</td><td valign='top' style='width:54.25pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23.5</p>
</td><td valign='top' style='width:63.7pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 10,107</p>
</td><td valign='top' style='width:63.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>26.7</p>
</td><td valign='top' style='width:63.7pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 9,149</p>
</td><td valign='top' style='width:63.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23.6</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Changes in foreign currency exchange rates did not have a significant impact on consolidated financial results in 2023. &#160;A stronger EUR and GBP in 3Q<span style='font-family:Symbol'>&#32;</span>2023 helped increase OUS S&amp;M expense by $3 and OUS G&amp;A expense by $51. An average slightly stronger USD for 9M 2023, reduced OUS S&amp;M expenses by $4, OUS G&amp;A expenses by $26 and OUS R&amp;D expenses by $1. The following table summarizes &#8220;constant currency&#8221; Operating Expenses in 3Q and 9M 2023 compared to the same periods in 2022 by Operating Expense (OE) category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>OE Category</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023 const FX</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023 const FX</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>S&amp;M:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;414</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;373</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,213</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,066</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>G&amp;A:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,784</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,560</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8,510</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,713</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>R&amp;D:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>138</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>112</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>415</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>370</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total OE:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,336</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,045</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 10,138</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 9,149</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>10</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>S&amp;M and R&amp;D expenses were higher primarily as a result of cost-of-living adjustments to employee salaries. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>A division of G&amp;A expenses by location follows. G&amp;A expenses include non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the Filshie Clip System, which is also separated out below:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:219.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>G&amp;A Expense Category</span></p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023</span></p>
</td><td valign='top' style='width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023</span></p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:219.15pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>IIA Amort&#8211; UK:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;504</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4.0</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;467</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.6</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,484</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.9</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,497</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.9</p>
</td></tr>
<tr><td valign='top' style='width:219.15pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>IIA Amort&#8211; CSI:</span></p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td><td valign='top' style='width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8.8</p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8.5</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,316</p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8.8</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,316</p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8.6</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:219.15pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Other&#8211; UK:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.5pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>171</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>132</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>498</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>428</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:219.15pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Other&#8211; US:</span></p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>912</span></p>
</td><td valign='top' style='width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>710</span></p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>2,752</span></p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>2,018</span></p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:219.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IRE:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>74</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>73</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>227</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>224</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:219.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUS:</p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>38</p>
</td><td valign='top' style='width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>39</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>107</p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>124</p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:219.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>CAN:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>31</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>34</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>100</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>106</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:219.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total G&amp;A:</p>
</td><td valign='top' style='width:54.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,835</p>
</td><td valign='top' style='width:54.15pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>22.7</p>
</td><td valign='top' style='width:54.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,560</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.8</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 8,484</p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>22.4</p>
</td><td valign='top' style='width:63.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 7,713</p>
</td><td valign='top' style='width:63.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.9</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Although the IIA amortization expense in either USD or GBP, depending on the location where expensed, was the same as in the prior year&#8217;s same periods, the 3Q 2023 Operating Income margin was diluted by 0.7 percentage points, and the 9M 2023 Operating Income margin was diluted by 0.2 percentage points, due to a lower sales denominator and the GBP FX rate difference. Non-cash IIA amortization expense was 57% of total G&amp;A expenses in both 3Q 2023 and 9M 2023. &#160;Litigation expenses, included in the Other-US G&amp;A Expense category above, were about 2.8% of sales in both 3Q 2023 and 9M 2023. &#160;Litigation expenses were 1.4% of sales in 3Q 2022 and 1.1% of sales in 9M 2022. &#160;In other words, higher litigation expenses reduced UTMD&#8217;s Operating Income margin by another 1.4 percentage-points in 3Q 2023, and another 1.7 percentage-points in 9M 2023.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS G&amp;A expenses in USD terms were $818 in 3Q 2023 compared to $745 in 3Q 2022. OUS G&amp;A expenses were $2,416 in 9M 2023 compared to $2,379 in 9M 2022. The constant currency table below shows how the changes in FX rates affected reported OUS G&amp;A expenses for 3Q 2023 ($51 higher) and 9M 2023 ($26 lower):</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>G&amp;A Expense Category</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023 const FX</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023 const FX</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>IIA Amort&#8211; UK:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;468</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;467</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,471</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,497</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Other&#8211; UK:</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>159</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>132</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>494</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>428</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IRE:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>69</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>73</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>230</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>224</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUS:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>39</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>39</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>101</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>124</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>CAN:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>32</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>34</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>94</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>106</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total OUS G&amp;A:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 767</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 745</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,390</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,379</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In summary, UTMD&#8217;s Operating Income margin in 3Q 2023 was 31.7% of sales compared to 39.7% of sales in 3Q 2022; and was 33.9% of sales in 9M 2023 compared to 38.0% of sales in 9M 2022. &#160;An explanation for changes in 3Q and 9M 2023 Operating Income margins from the prior year&#8217;s same periods follows:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:229.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Expense Category</span></p>
</td><td valign='top' style='width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>3Q Pct-Point Reduction</span></p>
</td><td valign='top' style='width:230.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>9M Pct-Point Reduction</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:229.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GPM difference:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>4.4</p>
</td><td valign='top' style='background-color:#CCEEFF;width:230.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2</p>
</td></tr>
<tr><td valign='top' style='width:229.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Litigation Expense (G&amp;A)</p>
</td><td valign='top' style='width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.4</p>
</td><td valign='top' style='width:230.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.7</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:229.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IIA Amortization Expense (G&amp;A)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.8</p>
</td><td valign='top' style='background-color:#CCEEFF;width:230.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.3</p>
</td></tr>
<tr><td valign='top' style='width:229.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>All Other Operating Expenses</span></p>
</td><td valign='top' style='width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>1.4</span></p>
</td><td valign='top' style='width:230.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>0.9</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:229.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Reduction in Operating Income margin:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>8.0</p>
</td><td valign='top' style='background-color:#CCEEFF;width:230.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>4.1</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Because of the significance of the IIA amortization expenses, and to remind stockholders of the history, the initial IIA amount of the 2011 Femcare UK purchase was &#163;23,998. &#160;After 12.5 years of amortization, the IIA balance is &#163;3,915 as of the end of 3Q 2023. &#160;For both 3Q 2023 and 3Q 2022 in GBP terms, the IIA amortization expenses were &#163;397. &#160;For both 9M 2023 and 9M 2022, the IIA amortization expenses were &#163;1,192. The converted USD amortization expense in each period then varied according to the USD/GBP FX rate, which explains the difference in IIA amortization expense in IIA Amort-UK row in the table above.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The initial amount of IIA for the 2019 acquisition of 4.75 years&#8217; remaining exclusive U.S. Filshie device distribution and intellectual property rights from CooperSurgical Inc (CSI) was $21,000. &#160;The straight-line amortization of the IIA is $1,105/ calendar quarter over the remaining 4.75 years of the prior distribution agreement at the time of acquisition. After 4.67 years of amortization, the CSI IIA balance as of September 30, 2023 is $368. The CSI IIA amortization expenses were the same in both 2023 and 2022 3Q and 9M periods.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Because the non-cash IIA amortization expenses represent a majority of UTMD&#8217;s Operating Expenses, UTMD provides the following table that separates the IIA amortization expenses from all other Operating Expenses:</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023</span></p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023</span></p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IIA amortization expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,609</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,573</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,800</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,813</p>
</td></tr>
<tr><td valign='top' style='width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>All other Operating expense</p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1,781</span></p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1,472</span></p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>5,307</span></p>
</td><td valign='top' style='width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>4,336</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:230.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total Operating Expenses:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;3,390</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;3,045</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;10,107</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;9,149</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:230.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Percent of Sales:</p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023</span></p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023</span></p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:230.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IIA amortization expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12.9%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12.1%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12.7%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12.4%</p>
</td></tr>
<tr><td valign='top' style='width:230.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>All other G&amp;A expense</p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>14.2%</span></p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>11.4%</span></p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>14.0%</span></p>
</td><td valign='top' style='width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>11.2%</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:230.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total G&amp;A Expenses:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>27.1%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23.5%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>26.7%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23.6%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Therefore, when the two Filshie-related IIA balances are fully amortized, stockholders can look forward to a substantial increase in EBT. The Femcare acquisition IIA amortization expense has just 2.5 more years to run at about $503 per quarter using the same USD/GBP FX rate as in 3Q 2023. &#160;The CSI IIA amortization expense will be fully amortized in 4Q 2023 with just a $368 remaining expense.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>e)</kbd><kbd style='margin-left:22.5pt'></kbd>Non-operating expense/ Non-operating income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Non-operating expense includes 1) bank fees; 2) losses from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) losses from disposition of assets. &#160;Non-operating income includes 1) investment income from cash balances; 2) rent of underutilized property; 3) royalties received from licensing the Company&#8217;s technology; 4) gains from dispositions of assets; and 5) gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>11</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s net Non-operating income in 3Q 2023 was $811 compared to $198 in 3Q 2022. &#160;Net non-operating income in 9M 2023 was $2,239 compared to $348 in 9M 2022. &#160;&#160;&#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 3Q 2023 a gain of $1 resulted from remeasurement of the value of foreign currency bank balances compared to a $2 loss in 3Q 2022. UTMD recognized a $6 loss from remeasurement of the value of foreign currency bank balances in both 9M 2023 and 9M 2022. &#160;Royalties received were $0 in 3Q 2023 compared to $5 in 3Q 2022, and $10 in 9M 2023 compared to $15 in 9M 2022. Interest earned on cash balances were $743 and $2,038 in 3Q and 9M 2023 respectively, compared to interest of $152 and $211 in 3Q and 9M 2022 respectively. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>f)</kbd><kbd style='margin-left:22.5pt'></kbd>Income Before Income Taxes (EBT)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EBT results from subtracting net Non-operating expense or adding net Non-operating income from or to, as applicable, Operating Income. &#160;Consolidated 3Q 2023 EBT was $4,781 (38.2% of sales) compared to $5,339 (41.2% of sales) in 3Q 2022. Consolidated 9M 2023 EBT was $15,072 (39.8% of sales) compared to $15,068 (38.9% of sales) in 9M 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The EBT of Utah Medical Products, Inc. in the U.S. was $7,955 in 9M 2023 compared to $9,607 in 9M 2022. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 6,279 in 9M 2023 compared to EUR 5,074 in 9M 2022. The US GAAP EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (53) in 9M 2023 compared to GBP (279) in 9M 2022. The EBT of Utah Medical Products Canada, Inc. (dba Femcare Canada) was CAD 474 in 9M 2023 compared to CAD 443 in 9M 2022. The EBT of UTMD&#8217;s manufacturing subsidiaries varies as a result of intercompany shipments which are eliminated in the consolidation of financial results.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2023 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) was $6,604 compared to $7,111 in 3Q 2022. &#160;Adjusted consolidated EBITDA was $20,520 in 9M 2023 compared to $20,487 in 9M 2022. Adjusted consolidated EBITDA for the previous four calendar quarters (TTM) was $27,924 as of September 30, 2023.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 52.8% in 3Q 2023 compared to 54.9% in 3Q 2022, reflecting the lower 3Q 2023 GPM. &#160;UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 54.2% in 9M 2023 compared to 52.9% in 9M 2022. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Management believes that this non-US GAAP operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance during a difficult economic period of time. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2023</span></p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2022</span></p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2023</span></p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2022</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EBT</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,781</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;5,339</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 15,072</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 15,068</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Depreciation Expense</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>155</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>152</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>465</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>454</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>503</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 467</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,484</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,497</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CSI IIA Amortization Expense</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1,105</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1,105</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,316</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,316</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 8</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 8</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>24</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>24</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Stock Option Compensation Expense</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 53</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 38</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>152</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>121</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:318.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Interest Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> -</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> -</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:318.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(1)</p>
</td><td valign='top' style='width:89.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7</p>
</td><td valign='top' style='width:96.25pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:318.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 6,604</p>
</td><td valign='top' style='background-color:#CCEEFF;width:89.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 7,111</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$20,520</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.25pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$20,487</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>g)</kbd><kbd style='margin-left:22.5pt'></kbd>Net Income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net Income is EBT minus a provision for income taxes. &#160;Net Income in 3Q 2023 of $3,935 (31.5% of sales) was 8.1% lower than Net Income of $4,280 (33.0% of sales) in 3Q 2022. Net Income in 9M 2023 of $12,349 (32.6% of sales) was 3.6% higher than Net Income of $11,918 (30.8% of sales) in 9M 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The average consolidated income tax provisions (as a % of the same period EBT) in 3Q 2023 and 3Q 2022 were 17.7% and 19.8% respectively, and were 18.1% and 20.9% in 9M 2023 and 9M 2022 respectively. The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. The lower 2023 tax provision rates resulted from the EBT of Utah Medical Products, Ltd (Ireland), with the lowest sovereignty corporate income tax rate, growing disproportionately more than UTMD&#8217;s EBT from other sovereign entities, and a portion of UTMD&#8217;s 2023 Non-operating Income generated from interest on high grade tax-exempt municipal bonds. UTMD has consistently paid millions of dollars in income taxes annually. The basic corporate income tax rates in each of the sovereignties were the same as in the prior year, except for the UK.  The UK corporate income rate changed from 19% to 25% on April 1, 2023. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>12</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>h)</kbd><kbd style='margin-left:22.5pt'></kbd>Earnings Per Share (EPS)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EPS are consolidated Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value). </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Diluted EPS in 3Q 2023 were $1.081 compared to $1.178 in 3Q 2022, an 8.2% decrease. Diluted EPS in 9M 2023 were $3.394 compared to diluted EPS of $3.265 in 9M 2022, a 4.0% increase. Diluted shares were 3,638,723 in 3Q 2023 compared to 3,634,235 in 3Q 2022. The higher diluted shares in 3Q 2023 were the result of exercise of employee options. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The number of shares used for calculating 3Q 2023 EPS was higher than September 30, 2023 actual outstanding shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. Outstanding shares at the end of 3Q 2023 were 3,629,525 compared to 3,627,767 at the end of calendar year 2022. The difference was due to 1,758 shares in employee option exercises during 9M 2023. For comparison, actual outstanding shares were 3,625,195 at the end of 3Q 2022. The total number of outstanding unexercised employee and outside director options at September 30, 2023 was 65,301 at an average exercise price of $73.83, including shares awarded but not yet vested. &#160;This compares to 49,895 unexercised option shares at the end of 3Q 2022 at an average exercise price of $69.00/ share, including shares awarded but not vested.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The number of shares added as a dilution factor for 3Q 2023 was 9,309 compared to 9,220 in 3Q 2022. The number of shares added as a dilution factor for 9M 2023 was 9,918 compared to 9,424 in 9M 2022. In October 2022, 20,600 option shares were awarded to 40 employees at an exercise price of $82.60. &#160;No options have been awarded in 2023. &#160;UTMD paid $1,071 ($0.295/share) in dividends to stockholders in 3Q 2023 compared to $1,051 ($0.290/ share) paid in 3Q 2022. Dividends paid to stockholders during 3Q 2023 were 27% of 3Q 2023 Net Income. UTMD paid $3,211 ($0.295/share) in dividends to stockholders in 9M 2023 compared to $2,111 ($0.290/ share) paid in 9M 2022. The difference was due to an earlier payment of a special dividend at the end of 2021 instead of in 1Q 2022. No UTMD shares have been purchased in the open market in 2023. In 2Q 2022, the Company purchased 30,105 UTMD shares at an average cost of $82.88/ share. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. </p>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>i) </kbd><kbd style='margin-left:22.5pt'></kbd>Return on Stockholder Equity (ROE) and Stock Value&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated stockholders&#8217; equity for the applicable time period. &#160;After payment of cash dividends to stockholders, annualized ROE in 9M 2023 was 10% compared to annualized ROE of 12% in 9M 2022. Before the payment of dividends, annualized ROE in 9M 2023 was 14% compared to 15% in 9M 2022.  The lower ROE in 9M 2023 was due to an 11% increase in average accumulated stockholders&#8217; equity divided into Net Income that grew only 4%. &#160;The larger increase in average stockholders&#8217; equity was due to accumulation of cash. Targeting a high ROE of 20% (before dividends) remains a key financial objective for UTMD management.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD paid $1,071 ($0.295/share) in dividends to stockholders in 3Q 2023 compared to $1,051 ($0.290/ share) paid in 3Q 2022. Dividends paid to stockholders during 3Q 2023 were 27% of 3Q 2023 Net Income. UTMD paid $3,211 ($0.295/share) in dividends to stockholders in 9M 2023 compared to $2,111 ($0.290/ share) paid in 9M 2022. The main difference was due to an earlier payment of a special dividend at the end of 2021 instead of in 1Q 2022. Dividends paid to stockholders during 9M 2023 were 26% of 9M 2023 Net Income.</p>
<p style='font:10pt Times New Roman;margin:0'> &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s closing share price at the end of 3Q 2023 was $86.00, down from the closing price of $93.20 three months earlier at the end of 2Q 2023, and the closing price of $100.53 nine months earlier at the end of 2022. UTMD&#8217;s closing share price at the end of 3Q 2022 was $85.31. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Liquidity and Capital Resources</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>j)</kbd><kbd style='margin-left:22.5pt'></kbd>Cash flows&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $16,949 in 9M 2023 compared to $15,467 in 9M 2022. &#160;The $1,483 higher cash provided by operating activities in 9M 2023 was due to $431 higher Net Income and to working capital differences from 1) a $1,141 smaller increase in inventories in 9M 2023 compared to 9M 2022 and 2) a $2,133 decrease in trade accounts receivable in 9M 2023 instead of a $1,071 increase in 9M 2022, which were offset by 1) a $711 decrease in accounts payable instead of a $540 increase in 9M 2022 and 2) a $1,093 decrease in accrued expenses instead of a $1,075 increase in 9M 2022. &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>13</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>Capital expenditures for property and equipment (PP&amp;E) were $549 in 9M 2023 compared to $771 in 9M 2022.  &#160;The capital expenditures in both years were due to expansion in manufacturing equipment in both Utah and Ireland. Capital expenditures for intangible assets were none in 9M 2023 compared to $9 in 9M 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD made cash dividend payments of $3,211 in 9M 2023 compared to $2,111 in 9M 2022. &#160;A special dividend declared in 4Q 2021 was paid earlier in December 2021 instead of January 2022. There were $2,495 in share repurchases in 9M 2022 compared to no share repurchases in 9M 2023. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 9M 2023 the Company received $117 and issued 1,758 shares of stock on the exercise of employee and director stock options. Option exercises in 9M 2023 were at an average price of $66.40 per share. In comparison, in 9M 2022 the Company received $43 and issued 563 shares of stock on the exercise of employee and director stock options. Option exercises in 9M 2022 were at an average price of $75.98 per share. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company may utilize cash not needed to support normal operations in one or a combination of the following: &#160;1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>k)</kbd><kbd style='margin-left:22.5pt'></kbd>Assets and Liabilities&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>September 30, 2023 total consolidated assets were $131,243, a net increase of $7,369 from December 31, 2022. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Consolidated Current Assets alone increased $11,928, as cash increased $13,157 and inventories increased $895, while receivables declined by $2,051. The smaller total asset increase was due to an offsetting $4,559 decrease in long term assets, Net Intangible Assets and Property, Plant &amp; Equipment (PP&amp;E). Net Intangible Assets declined $4,682 as a result of amortization but combined with a stronger GBP for remaining Femcare IIA. OUS PP&amp;E decreased $199, primarily as a result of $179 in USD-denominated depreciation, but also, except for the GBP, weaker quarter-ending foreign currencies for remaining OUS PP&amp;E assets.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s Ireland subsidiary EUR-denominated assets and liabilities on September 30, 2023 were translated into USD at an FX rate 1.0% lower (weaker EUR relative to the USD) than the FX rate at the end of 2022. UTMD&#8217;s UK subsidiary GBP-denominated assets were translated into USD at an FX rate 1.1% higher (stronger GBP) than the FX rate at the end of 2022. &#160;UTMD&#8217;s Australia subsidiary AUD-denominated assets were translated into USD at an FX rate 5.2% lower (weaker AUD) than the FX rate at the end of 2022. &#160;UTMD&#8217;s Canada subsidiary CAD-denominated assets were translated into USD at an FX rate about the same as the FX rate at the end of 2022. &#160;The net book value of WW consolidated PP&amp;E increased $123 at September 30, 2023 from the end of 2022 due to the period-ending changed FX rates above, $549 in new asset purchases and $465 in depreciation. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Working capital (Current Assets minus Current Liabilities) was $97,670 at September 30, 2023 compared to $83,959 at December 31, 2022.  The primary sources of the $13,711 working capital increase were from consolidated increases of $13,157 in cash and $895 in inventories together with decreases of $707 in Accounts Payable and $1,076 in Accrued Liabilities, offset by a $2,051 decline in receivables. &#160;In other words, independently from the change in cash, a $1,783 decrease in consolidated Current Liabilities together with the $895 inventory increase offset the $2,051 decrease in receivables. Management believes that UTMD&#8217;s working capital remains sufficient to meet normal operating needs, as well as providing a cushion for unpredictable short-term negative events, new capital expenditures and continued cash dividend payments to stockholders.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>September 30, 2023 Net Intangible Assets (goodwill plus other intangible assets, less amortization) declined $4,682 from the end of 2022. &#160;No new intangible assets were acquired in 9M 2023. &#160;At September 30, 2023, Net Intangible Assets including goodwill were less than 15% of consolidated Total Assets compared to 19% at year-end 2022, and 20% one year ago at September 30, 2022. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The long-term deferred tax liability (DTL) balance for Femcare IIA ($9,084 on the date of the acquisition) was $1,195 (&#163;979) at September 30, 2023, compared to $1,513 (&#163;1,253) at December 31, 2022, and $1,479 (&#163;1,328) at September 30, 2022. &#160;Reduction of the DTL occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare IIA (because the amortization expense is not tax deductible in the UK). The DTL declined $318 at September 30, 2023 from December 31, 2022, as a result of 9M 2023 amortization expense of $1,484, which reduced the DTL balance by $371 (using UK tax rate = 25%). The remaining difference was due to the FX rate when converting the GBP to USD at September 30, 2023.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s total debt ratio (Total Liabilities/ Total Assets) as of September 30, 2023 was less than 6%, including a remaining $1,675 Repatriation Tax liability from the 2017 &#8220;Tax Cuts and Jobs Act&#8221; payable over another two years. &#160;UTMD&#8217;s total debt ratio as of December 31, 2022 was 8%, and as of September 30, 2022 was 9%. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The $7,369 increase in Total Liabilities and Stockholders&#8217; Equity (same as the increase in Total Assets) at September 30, 2023 from December 31, 2022 was due to an increase in Stockholders&#8217; Equity, as Total Liabilities declined $2,079. Stockholders&#8217; Equity increased $9,448 at September 30, 2023 from December 31, 2022. Stockholders&#8217; equity increased during 9M 2023 from $12,349 in Net Profit, but was reduced by $3,211 in dividends paid to stockholders.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>14</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>l)</kbd><kbd style='margin-left:22.5pt'></kbd>Management's Outlook&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>As outlined in its December 31, 2022 SEC 10-K report, UTMD&#8217;s plan for 2023 was to</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:31.5pt'>1) &#160;leverage distribution and manufacturing synergies by further integrating capabilities and resources in UTMD&#8217;s multinational operations; &#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:31.5pt'>2) &#160;expand manufacturing capacity at a time when resources are scarce;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:31.5pt'>3) &#160;focus on effectively differentiating the benefits of the Filshie Clip System in the U.S.;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:31.5pt'>4) &#160;introduce additional products helpful to clinicians through product development;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:31.5pt'>5) &#160;continue to achieve excellent overall financial operating performance;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:31.5pt'>6) &#160;utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued; and</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:31.5pt'>7) &#160;remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult burdens on small, innovative companies.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Generally, the Company continues to execute its 2023 plan outlined above. &#160;In 9M 2023, UTMD achieved higher Net Income and EPS, achieving continued excellent overall financial performance. As expected, 2023 OEM revenues substantially declined and &#8220;sticky&#8221; inflation on manufacturing costs challenged UTMD&#8217;s GPM. &#160;But the increase in Non-operating Income from higher interest on cash reserves more than offset the decline in Operating Income from a lower GPM combined with inflation in Operating Expenses including higher litigation expenses. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>m)</kbd><kbd style='margin-left:22.5pt'></kbd>Accounting Policy Changes&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>None</p>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>Forward-Looking Information</b>. &#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>15</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a10'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and, starting in 2017, in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .9448, .9351 and 1.0217 EUR per USD as of September 30, 2023, December 31, 2022 and September 30, 2022, respectively. &#160;Exchange rates were .8188, .8280 and .8984 GBP per USD as of September 30, 2023, December 31, 2022 and September 30, 2022, respectively. &#160;Exchange rates were 1.5505, 1.4695 and 1.5536 AUD per USD on September 30, 2023, December 31, 2022, and September 30, 2022, respectively. &#160;Exchange rates were 1.3537, 1.3532, and 1.3751 CAD per USD on September 30, 2023, December 31, 2022, and September 30, 2022, respectively. UTMD manages its foreign currency risk without separate hedging transactions by invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur and by optimizing global account structures through liquidity management accounts.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a11'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 4. Controls and Procedures</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of September 30, 2023. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of September 30, 2023, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the nine months ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>16</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a12'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART II - OTHER INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a13'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1. Legal Proceedings</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The Company is currently a party in litigation incidental to its business related to the safety of the Filshie Clip System, which remains approved under a PMA by the U.S. FDA as safe and effective. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a14'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1A. Risk Factors</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#333333'>In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Legislative or executive order healthcare interference in the United States</span> renders the U.S. medical device marketplace unpredictable. A fully government-run healthcare system would likely eliminate healthcare consumer choice as well as commercial incentives for innovation. &#160;Restrictions on &#8220;nonessential&#8221; medical procedures during a pandemic reduce the demand for certain of UTMD&#8217;s medical devices. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>Increasing regulatory burdens, including premarketing approval delays, may result in significant loss of revenue, unpredictable costs and loss of management focus on developing and marketing products that improve the quality of healthcare: </span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Thousands of small focused medical device manufacturers including UTMD that do not have the overhead structure that the few large medical device companies can afford are increasingly burdened with bureaucratic and underqualified regulator demands that are not reasonably related to assuring the safety or effectiveness of the devices that they provide. &#160;Premarketing submission administrative burdens, and substantial &#8220;user fees&#8221; or notified body review fees, represent a significant non-clinical and/or non-scientific barrier to new product introduction, resulting in lack of investment or delays to revenues from new or improved devices. &#160;The risks associated with such circumstances relate not only to substantial out-of-pocket costs, including potential litigation in millions of dollars, but also loss of business and a diversion of attention of key employees for an extended period of time from managing their normal responsibilities, particularly in new product development and routine quality assurance activities. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>Group Purchasing Organizations (GPOs) in the U.S. add non-productive costs, weaken the Company&#8217;s marketing and sales efforts and cause lower revenues by restricting access:</span> &#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD&#8217;s, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Otherwise, their business model based on &#8220;kickbacks&#8221; would be a violation of law. &#160;Despite rhetoric otherwise, these bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily driven by collection of their administrative fees. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>The Company&#8217;s business strategy may not be successful in the future:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:8.55pt'></kbd>As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable and overly cumbersome regulatory environment, the Company&#8217;s views of the future and product/ market strategy may not yield financial results consistent with the past.&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage: &#160;</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>An aging population is placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. &#160;Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. &#160;As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. &#160;Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD&#8217;s clinical advantages more difficult. &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>17</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>A product liability lawsuit could result in significant legal expenses and a large award against the Company: </span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. &#160;In any lawsuit where an individual plaintiff suffered permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>The Company&#8217;s reliance on third party distributors in some markets may result in less predictable revenues:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s distributors have varying expertise in marketing and selling specialty medical devices. &#160;They also sell other devices that may result in less focus on the Company&#8217;s products. &#160;In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, a distributor of UTMD&#8217;s products may eventually become a competitor with a cheaper but lower quality version of UTMD&#8217;s devices. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>The loss of one or more key employees could negatively affect UTMD performance:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. &#160;The Company&#8217;s benefits programs are key to recruiting and retaining talented employees. &#160;An increase in UTMD&#8217;s employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>Fluctuations in foreign currencies relative to the USD can result in significant differences in period-to-period financial results:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Since a significant portion of UTMD&#8217;s sales are invoiced in foreign currencies and consolidated financial results are reported in USD terms, a stronger USD can have negative revenue effects. Conversely, a weaker USD would increase foreign subsidiary operating costs in USD terms. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. &#160;For the portion invoiced in a foreign currency, not only USD-denominated sales are reduced, but also gross profits may be reduced because finished distributed devices and/or U.S. made raw materials and components are likely being purchased in fixed USD.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Trade restrictions and /or tariffs resulting from changing government trade policies have the potential to disrupt UTMD&#8217;s supply chain.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The COVID-19 pandemic could continue to disrupt UTMD&#8217;s supply chain or interfere with normal business operations due to the loss of employee availability and rapidly rising input costs.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a15'></a><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><b>Item 2.</b></kbd><kbd style='margin-left:37.8pt'></kbd><b>Unregistered Sales of Equity Securities and Use of Proceeds</b>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD did not purchase any of its own securities in 9M 2023. &#160;During 2Q 2022/ 9M 2022 UTMD purchased 30,105 of its shares in the open market for $2,495 including commissions and fees ($82.88/ share.)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a17'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 6. &#160;Exhibits </b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:14.4pt'><td valign='bottom' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Exhibit #</span></p>
</td><td valign='bottom' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Title of Document</span></p>
</td></tr>
<tr style='height:3.6pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.1</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex31z1.htm' style='text-decoration:none'>Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex31z2.htm' style='text-decoration:none'>Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.1</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex32z1.htm' style='text-decoration:none'>Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex32z2.htm' style='text-decoration:none'>Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>101</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL): &#160;(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders&#8217; Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.</p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>104</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>18</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a18'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>SIGNATURES</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:28.8pt'></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd>REGISTRANT&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;11/13/23 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Kevin L. Cornwell&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>CEO&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;11/13/23 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Brian L. Koopman&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:219.1pt'></kbd>Principal Financial Officer&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>19</span></p>
<p style='font:10pt CG Times;margin:0'>&#160;</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: November 13, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt CG Times;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-15.3pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: November 13, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-73.8pt;margin-left:73.8pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>November 13, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 32.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>November 13, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureInventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureInventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureWarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureRevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureEarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureSubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CSI Distribution Agreement Purchase Disclosure</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of Right of Use Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for (recovery of) losses on accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Remaining months of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Remaining months of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:to='lab_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; investments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:to='lab_us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CooperSurgical Inc</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the CooperSurgical Inc, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CoopersurgicalIncMember' xlink:to='lab_fil_CoopersurgicalIncMember'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition [Axis]</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the description of Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='lab_fil_DistributionRightsAcquisitionAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyAccrual' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard and Extended Product Warranty Accrual</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyAccrual' xlink:to='lab_us-gaap_ProductWarrantyAccrual'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesNoncurrent' xlink:to='lab_us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='lab_fil_DistributionRightsAcquisitionDomain'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquireIntangibleAssets' xlink:to='lab_us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='lab_us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements and Changes in Accounting Principles</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:to='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PolicyTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Policies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='lab_us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Earnings Per Share, Basic and Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:to='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='lab_us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2023, 3,629 shares and December 31, 2022, 3,628 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllocatedShareBasedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allocated Share-based Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllocatedShareBasedCompensationExpense' xlink:to='lab_us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finite-Lived Intangible Assets Acquired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:to='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work-in-process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in operating assets and liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='lab_us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, diluted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Assets' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='16.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='22.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='26.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='27.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1' use='optional' order='28.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='30.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureInventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureInventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureWarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureRevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureEarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureSubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleOfRevenuesByProductCategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AllocatedShareBasedCompensationExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProductWarrantyAccrual' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230930.xsd#fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20230930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVDV8XYZJ]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2023' xmlns:srt='http://fasb.org/srt/2023' xmlns:fil='http://www.utahmed.com/20230930' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://www.utahmed.com/20230930' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2022-03-31' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
				<link:definition>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
				<link:definition>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare" id="idr_DisclosureEarningsPerShare">
				<link:definition>000150 - Disclosure - Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventories" id="idr_DisclosureInventories">
				<link:definition>000100 - Disclosure - Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails" id="idr_DisclosureStockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve" id="idr_DisclosureWarrantyReserve">
				<link:definition>000120 - Disclosure - Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition" id="idr_DisclosureRevenueRecognition">
				<link:definition>000130 - Disclosure - Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails" id="idr_DisclosureWarrantyReserveDetails">
				<link:definition>000230 - Disclosure - Warranty Reserve (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
				<link:definition>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
				<link:definition>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation" id="idr_DisclosureStockBasedCompensation">
				<link:definition>000110 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation" id="idr_DisclosureBasisOfPresentation">
				<link:definition>000080 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
				<link:definition>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
				<link:definition>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
				<link:definition>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
				<link:definition>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents" id="idr_DisclosureSubsequentEvents">
				<link:definition>000160 - Disclosure - Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import namespace='http://xbrl.sec.gov/dei/2023' schemaLocation='https://xbrl.sec.gov/dei/2023/dei-2023.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2023' schemaLocation='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfRevenuesByProductCategoryTextBlock' name='ScheduleOfRevenuesByProductCategoryTextBlock'/>
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrldt:dimensionItem' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionAxis' name='DistributionRightsAcquisitionAxis'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionDomain' name='DistributionRightsAcquisitionDomain'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CoopersurgicalIncMember' name='CoopersurgicalIncMember'/>
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' name='RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915386069760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915386247136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; investments</a></td>
<td class="nump">$ 88,209<span></span>
</td>
<td class="nump">$ 75,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">3,487<span></span>
</td>
<td class="nump">5,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,709<span></span>
</td>
<td class="nump">8,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">101,847<span></span>
</td>
<td class="nump">89,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,346<span></span>
</td>
<td class="nump">10,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,424<span></span>
</td>
<td class="nump">13,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">53,042<span></span>
</td>
<td class="nump">52,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(47,416)<span></span>
</td>
<td class="num">(42,378)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">5,626<span></span>
</td>
<td class="nump">10,377<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">131,243<span></span>
</td>
<td class="nump">123,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,666<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,177<span></span>
</td>
<td class="nump">5,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,541<span></span>
</td>
<td class="nump">9,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2023, 3,629 shares and December 31, 2022, 3,628 shares</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(11,999)<span></span>
</td>
<td class="num">(12,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">135,144<span></span>
</td>
<td class="nump">126,006<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">123,702<span></span>
</td>
<td class="nump">114,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 131,243<span></span>
</td>
<td class="nump">$ 123,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915386007056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915384564304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 12,505<span></span>
</td>
<td class="nump">$ 12,955<span></span>
</td>
<td class="nump">$ 37,891<span></span>
</td>
<td class="nump">$ 38,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">4,769<span></span>
</td>
<td class="nump">14,951<span></span>
</td>
<td class="nump">14,838<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">7,359<span></span>
</td>
<td class="nump">8,186<span></span>
</td>
<td class="nump">22,940<span></span>
</td>
<td class="nump">23,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">9,693<span></span>
</td>
<td class="nump">8,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">10,107<span></span>
</td>
<td class="nump">9,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">5,141<span></span>
</td>
<td class="nump">12,833<span></span>
</td>
<td class="nump">14,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">4,781<span></span>
</td>
<td class="nump">5,339<span></span>
</td>
<td class="nump">15,072<span></span>
</td>
<td class="nump">15,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,935<span></span>
</td>
<td class="nump">$ 4,280<span></span>
</td>
<td class="nump">$ 12,349<span></span>
</td>
<td class="nump">$ 11,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="nump">$ 3.39<span></span>
</td>
<td class="nump">$ 3.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding - basic</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="num">$ (1,012)<span></span>
</td>
<td class="num">$ (2,572)<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (5,377)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="nump">$ 1,708<span></span>
</td>
<td class="nump">$ 12,390<span></span>
</td>
<td class="nump">$ 6,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915386005776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915384318288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="num">$ (9,054)<span></span>
</td>
<td class="nump">$ 115,314<span></span>
</td>
<td class="nump">$ 107,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(947)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,548)<span></span>
</td>
<td class="num">(2,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,377)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,162)<span></span>
</td>
<td class="num">(3,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,918<span></span>
</td>
<td class="nump">11,918<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="num">(14,431)<span></span>
</td>
<td class="nump">122,521<span></span>
</td>
<td class="nump">108,185<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2022</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,858)<span></span>
</td>
<td class="nump">119,293<span></span>
</td>
<td class="nump">107,471<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,572)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="num">(14,431)<span></span>
</td>
<td class="nump">122,521<span></span>
</td>
<td class="nump">108,185<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2022</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="num">(12,039)<span></span>
</td>
<td class="nump">126,006<span></span>
</td>
<td class="nump">114,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,212)<span></span>
</td>
<td class="num">(3,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,349<span></span>
</td>
<td class="nump">12,349<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="num">(11,999)<span></span>
</td>
<td class="nump">135,144<span></span>
</td>
<td class="nump">123,702<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="num">(10,986)<span></span>
</td>
<td class="nump">132,279<span></span>
</td>
<td class="nump">121,762<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,935<span></span>
</td>
<td class="nump">3,935<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
<td class="num">$ (11,999)<span></span>
</td>
<td class="nump">$ 135,144<span></span>
</td>
<td class="nump">$ 123,702<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915384213696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 12,349<span></span>
</td>
<td class="nump">$ 11,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">4,824<span></span>
</td>
<td class="nump">4,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) losses on accounts receivable</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of Right of Use Assets</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and other receivables</a></td>
<td class="nump">2,133<span></span>
</td>
<td class="num">(1,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(925)<span></span>
</td>
<td class="num">(2,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(712)<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,093)<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">16,949<span></span>
</td>
<td class="nump">15,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(549)<span></span>
</td>
<td class="num">(771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(549)<span></span>
</td>
<td class="num">(780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(3,211)<span></span>
</td>
<td class="num">(2,112)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(3,094)<span></span>
</td>
<td class="num">(4,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">13,157<span></span>
</td>
<td class="nump">8,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">75,052<span></span>
</td>
<td class="nump">60,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">88,209<span></span>
</td>
<td class="nump">69,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915386066832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2022. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915384524960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(2) Recent Accounting Standards. </p>
 <p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915387783360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at September 30, 2023, and December 31, 2022, consisted of the following:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:411.4pt" valign="top"></td><td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> September 30, 2023</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2022</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,338</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,896</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:31.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,654</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,193</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,717</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,725</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,709</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,814</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915475684128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At September 30, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2023, and 2022, the Company recognized $53 and $38, respectively, in stock based compensation cost. &#160;In the nine months ended September 30, 2023, and 2022, the Company recognized $153 and $121, respectively, in stock based compensation cost.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915388592384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022, or September 30, 2023. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915475684128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) Global 3Q 2023 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,066</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">357</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,423</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,600</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,772</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,372</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,363</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">521</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,884</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,236</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,590</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,826</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,265</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,240</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,505</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 9M 2023 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,725</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">788</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,513</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,805</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,076</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">16,881</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,892</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,150</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,042</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,045</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,410</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,455</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">21,467</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">16,424</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">37,891</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915388592384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">CSI Distribution Agreement Purchase Disclosure</a></td>
<td class="text"><p style="font:12pt Times New Roman;margin:0;color:#000000"><span style="font-size:10pt">(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) as of February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over a remaining one month of life as of September 30, 2023 of the prior CSI distribution agreement with Femcare Ltd.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915388520192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3rd quarter 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Nine months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"></td><td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,935</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,280</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,349</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,918</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:136.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,629</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,625</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,629</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,641</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,639</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,634</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,638</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,650</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:136.85pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.08</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.18</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.40</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.27</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.08</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.18</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.39</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.26</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915388765248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915388520192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915388592384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:411.4pt" valign="top"></td><td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> September 30, 2023</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2022</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,338</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,896</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:31.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,654</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,193</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,717</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,725</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,709</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,814</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915387783360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock', window );">Schedule Of Revenues By Product Category</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,066</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">357</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,423</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,600</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,772</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,372</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,363</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">521</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,884</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,236</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,590</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,826</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,265</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,240</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,505</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 9M 2023 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,725</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">788</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,513</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,805</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,076</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">16,881</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,892</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,150</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,042</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,045</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,410</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,455</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">21,467</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">16,424</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">37,891</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfRevenuesByProductCategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915387660192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Nine months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"></td><td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,935</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,280</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,349</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,918</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:136.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,629</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,625</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,629</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,641</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,639</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,634</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,638</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,650</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:136.85pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.08</p>
</td><td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.18</p>
</td><td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.40</p>
</td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.27</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:321.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:136.85pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.08</p>
</td><td style="width:39.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:161.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.18</p>
</td><td style="width:45.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:184.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.39</p>
</td><td style="width:34.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:172.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.26</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915385868640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 2,338<span></span>
</td>
<td class="nump">$ 1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">5,717<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 9,709<span></span>
</td>
<td class="nump">$ 8,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915386793376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915386069040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warranty Reserve (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915384179072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 12,505<span></span>
</td>
<td class="nump">$ 12,955<span></span>
</td>
<td class="nump">$ 37,891<span></span>
</td>
<td class="nump">$ 38,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">7,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 1,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915388771952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-Lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem', window );">Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139915378300224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,935<span></span>
</td>
<td class="nump">$ 4,280<span></span>
</td>
<td class="nump">$ 12,349<span></span>
</td>
<td class="nump">$ 11,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="nump">$ 3.39<span></span>
</td>
<td class="nump">$ 3.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>utmd-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:fil="http://www.utahmed.com/20230930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20230930.xsd" xlink:type="simple"/>
    <context id="D230101_230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="E23Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="E22Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="I231110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-11-10</instant>
        </period>
    </context>
    <context id="E22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Y23Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y22Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="D220101_220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="E21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E22Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="D230101_230930_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="E23Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="E23Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="E23Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="E23Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="E23Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Y23Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="E23Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="E23Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="E23Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="E23Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="E22_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E22Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E22Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E22Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Y22Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Y22Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Y22Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Y22Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="E22Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="E22Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="E22Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="E22Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="E21_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="D220101_220930_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="D220101_220930_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="D220101_220930_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="D220101_220930_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y23Q3_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D230930_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="D230101_230930" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="D230101_230930" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="D230101_230930" id="fact3">Yes</dei:EntityCurrentReportingStatus>
    <dei:AmendmentFlag contextRef="D230101_230930" id="fact4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="D230101_230930" id="fact5">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D230101_230930" id="fact6">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="D230101_230930">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="D230101_230930">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="D230101_230930">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D230101_230930">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D230101_230930">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D230101_230930">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D230101_230930">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D230101_230930">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D230101_230930">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D230101_230930">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D230101_230930">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D230101_230930">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D230101_230930">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D230101_230930">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D230101_230930">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D230101_230930">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D230101_230930">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="D230101_230930">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D230101_230930">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D230101_230930">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D230101_230930">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="D230101_230930">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="I231110" decimals="INF" unitRef="Shares">3629525</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E23Q3" decimals="-3" unitRef="USD">88209000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E22" decimals="-3" unitRef="USD">75052000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E23Q3" decimals="-3" unitRef="USD">3487000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E22" decimals="-3" unitRef="USD">5538000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="E23Q3" decimals="-3" unitRef="USD">9709000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E22" decimals="-3" unitRef="USD">8814000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="E23Q3" decimals="-3" unitRef="USD">442000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E22" decimals="-3" unitRef="USD">515000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E23Q3" decimals="-3" unitRef="USD">101847000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E22" decimals="-3" unitRef="USD">89919000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E23Q3" decimals="-3" unitRef="USD">10346000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E22" decimals="-3" unitRef="USD">10224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="E23Q3" decimals="-3" unitRef="USD">13424000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E22" decimals="-3" unitRef="USD">13354000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E23Q3" decimals="-3" unitRef="USD">53042000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E22" decimals="-3" unitRef="USD">52755000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E23Q3" decimals="-3" unitRef="USD">47416000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E22" decimals="-3" unitRef="USD">42378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E23Q3" decimals="-3" unitRef="USD">5626000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E22" decimals="-3" unitRef="USD">10377000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="E23Q3" decimals="-3" unitRef="USD">131243000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E22" decimals="-3" unitRef="USD">123874000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="E23Q3" decimals="-3" unitRef="USD">511000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E22" decimals="-3" unitRef="USD">1218000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E23Q3" decimals="-3" unitRef="USD">3666000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E22" decimals="-3" unitRef="USD">4742000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E23Q3" decimals="-3" unitRef="USD">4177000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E22" decimals="-3" unitRef="USD">5960000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E23Q3" decimals="-3" unitRef="USD">1196000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E22" decimals="-3" unitRef="USD">1514000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E23Q3" decimals="-3" unitRef="USD">1256000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E22" decimals="-3" unitRef="USD">1256000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E23Q3" decimals="-3" unitRef="USD">305000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E22" decimals="-3" unitRef="USD">341000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E23Q3" decimals="-3" unitRef="USD">607000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E22" decimals="-3" unitRef="USD">549000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="E23Q3" decimals="-3" unitRef="USD">7541000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E22" decimals="-3" unitRef="USD">9620000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E23Q3" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E22" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="E23Q3" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="E22" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="E23Q3" decimals="-3" unitRef="Shares">3629000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E23Q3" decimals="-3" unitRef="Shares">3629000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="E22" decimals="-3" unitRef="Shares">3628000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E22" decimals="-3" unitRef="Shares">3628000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="E23Q3" decimals="-3" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E22" decimals="-3" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E23Q3" decimals="-3" unitRef="USD">-11999000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E22" decimals="-3" unitRef="USD">-12039000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E23Q3" decimals="-3" unitRef="USD">521000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E22" decimals="-3" unitRef="USD">251000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E23Q3" decimals="-3" unitRef="USD">135144000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E22" decimals="-3" unitRef="USD">126006000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="E23Q3" decimals="-3" unitRef="USD">123702000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E22" decimals="-3" unitRef="USD">114254000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E23Q3" decimals="-3" unitRef="USD">131243000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E22" decimals="-3" unitRef="USD">123874000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y23Q3" decimals="-3" unitRef="USD">12505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y22Q3" decimals="-3" unitRef="USD">12955000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D230101_230930" decimals="-3" unitRef="USD">37891000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D220101_220930" decimals="-3" unitRef="USD">38707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y23Q3" decimals="-3" unitRef="USD">5146000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y22Q3" decimals="-3" unitRef="USD">4769000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D230101_230930" decimals="-3" unitRef="USD">14951000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D220101_220930" decimals="-3" unitRef="USD">14838000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="Y23Q3" decimals="-3" unitRef="USD">7359000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="Y22Q3" decimals="-3" unitRef="USD">8186000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="D230101_230930" decimals="-3" unitRef="USD">22940000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="D220101_220930" decimals="-3" unitRef="USD">23869000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y23Q3" decimals="-3" unitRef="USD">3252000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y22Q3" decimals="-3" unitRef="USD">2933000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D230101_230930" decimals="-3" unitRef="USD">9693000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D220101_220930" decimals="-3" unitRef="USD">8779000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y23Q3" decimals="-3" unitRef="USD">138000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y22Q3" decimals="-3" unitRef="USD">112000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D230101_230930" decimals="-3" unitRef="USD">414000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D220101_220930" decimals="-3" unitRef="USD">370000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="Y23Q3" decimals="-3" unitRef="USD">3390000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="Y22Q3" decimals="-3" unitRef="USD">3045000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D230101_230930" decimals="-3" unitRef="USD">10107000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D220101_220930" decimals="-3" unitRef="USD">9149000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="Y23Q3" decimals="-3" unitRef="USD">3969000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="Y22Q3" decimals="-3" unitRef="USD">5141000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D230101_230930" decimals="-3" unitRef="USD">12833000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D220101_220930" decimals="-3" unitRef="USD">14720000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y23Q3" decimals="-3" unitRef="USD">812000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y22Q3" decimals="-3" unitRef="USD">198000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="D230101_230930" decimals="-3" unitRef="USD">2239000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="D220101_220930" decimals="-3" unitRef="USD">348000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Y23Q3" decimals="-3" unitRef="USD">4781000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Y22Q3" decimals="-3" unitRef="USD">5339000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="D230101_230930" decimals="-3" unitRef="USD">15072000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="D220101_220930" decimals="-3" unitRef="USD">15068000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y23Q3" decimals="-3" unitRef="USD">846000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y22Q3" decimals="-3" unitRef="USD">1059000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="D230101_230930" decimals="-3" unitRef="USD">2723000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="D220101_220930" decimals="-3" unitRef="USD">3150000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="Y23Q3" decimals="-3" unitRef="USD">3935000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q3" decimals="-3" unitRef="USD">4280000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D230101_230930" decimals="-3" unitRef="USD">12349000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D220101_220930" decimals="-3" unitRef="USD">11918000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic contextRef="Y23Q3" decimals="INF" unitRef="UsdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y22Q3" decimals="INF" unitRef="UsdPerShare">1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D230101_230930"
      decimals="INF"
      unitRef="UsdPerShare">3.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D220101_220930"
      decimals="INF"
      unitRef="UsdPerShare">3.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y23Q3" decimals="INF" unitRef="UsdPerShare">1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y22Q3" decimals="INF" unitRef="UsdPerShare">1.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D230101_230930"
      decimals="INF"
      unitRef="UsdPerShare">3.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D220101_220930"
      decimals="INF"
      unitRef="UsdPerShare">3.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y23Q3" decimals="-3" unitRef="Shares">3629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y22Q3" decimals="-3" unitRef="Shares">3625000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D230101_230930" decimals="-3" unitRef="Shares">3629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D220101_220930" decimals="-3" unitRef="Shares">3641000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y23Q3" decimals="-3" unitRef="Shares">3639000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y22Q3" decimals="-3" unitRef="Shares">3634000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D230101_230930" decimals="-3" unitRef="Shares">3638000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D220101_220930" decimals="-3" unitRef="Shares">3650000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y23Q3" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y22Q3" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="D230101_230930" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="D220101_220930" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y23Q3" decimals="-3" unitRef="USD">-1012000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y22Q3" decimals="-3" unitRef="USD">-2572000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D230101_230930" decimals="-3" unitRef="USD">41000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D220101_220930" decimals="-3" unitRef="USD">-5377000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y23Q3" decimals="-3" unitRef="USD">2923000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y22Q3" decimals="-3" unitRef="USD">1708000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="D230101_230930" decimals="-3" unitRef="USD">12390000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="D220101_220930" decimals="-3" unitRef="USD">6541000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss contextRef="D230101_230930" decimals="-3" unitRef="USD">12349000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D220101_220930" decimals="-3" unitRef="USD">11918000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="D230101_230930" decimals="-3" unitRef="USD">465000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="D220101_220930" decimals="-3" unitRef="USD">454000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="D230101_230930" decimals="-3" unitRef="USD">4824000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="D220101_220930" decimals="-3" unitRef="USD">4837000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D230101_230930" decimals="-3" unitRef="USD">-31000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D220101_220930" decimals="-3" unitRef="USD">21000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="D230101_230930" decimals="-3" unitRef="USD">39000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="D220101_220930" decimals="-3" unitRef="USD">39000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D230101_230930" decimals="-3" unitRef="USD">-284000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D220101_220930" decimals="-3" unitRef="USD">-409000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation contextRef="D230101_230930" decimals="-3" unitRef="USD">153000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="D220101_220930" decimals="-3" unitRef="USD">121000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="D230101_230930" decimals="-3" unitRef="USD">12000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="D220101_220930" decimals="-3" unitRef="USD">0</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D230101_230930" decimals="-3" unitRef="USD">-2133000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D220101_220930" decimals="-3" unitRef="USD">1059000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="D230101_230930" decimals="-3" unitRef="USD">925000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="D220101_220930" decimals="-3" unitRef="USD">2065000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D230101_230930" decimals="-3" unitRef="USD">-19000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D220101_220930" decimals="-3" unitRef="USD">5000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D230101_230930" decimals="-3" unitRef="USD">-712000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D220101_220930" decimals="-3" unitRef="USD">540000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="D230101_230930" decimals="-3" unitRef="USD">-1093000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="D220101_220930" decimals="-3" unitRef="USD">1075000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="D230101_230930" decimals="-3" unitRef="USD">4600000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="D220101_220930" decimals="-3" unitRef="USD">3549000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D230101_230930" decimals="-3" unitRef="USD">16949000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D220101_220930" decimals="-3" unitRef="USD">15467000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D230101_230930" decimals="-3" unitRef="USD">549000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D220101_220930" decimals="-3" unitRef="USD">771000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D230101_230930" decimals="-3" unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D220101_220930" decimals="-3" unitRef="USD">9000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D230101_230930" decimals="-3" unitRef="USD">-549000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D220101_220930" decimals="-3" unitRef="USD">-780000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D230101_230930" decimals="-3" unitRef="USD">117000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D220101_220930" decimals="-3" unitRef="USD">43000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="D230101_230930" decimals="-3" unitRef="USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="D220101_220930" decimals="-3" unitRef="USD">2495000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="D230101_230930" decimals="-3" unitRef="USD">3211000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="D220101_220930" decimals="-3" unitRef="USD">2112000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D230101_230930" decimals="-3" unitRef="USD">-3094000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D220101_220930" decimals="-3" unitRef="USD">-4564000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="D230101_230930" decimals="-3" unitRef="USD">-149000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="D220101_220930" decimals="-3" unitRef="USD">-1586000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D230101_230930" decimals="-3" unitRef="USD">13157000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D220101_220930" decimals="-3" unitRef="USD">8537000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E22" decimals="-3" unitRef="USD">75052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E21" decimals="-3" unitRef="USD">60974000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E23Q3" decimals="-3" unitRef="USD">88209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E22Q3" decimals="-3" unitRef="USD">69511000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="D230101_230930" decimals="-3" unitRef="USD">3489000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="D220101_220930" decimals="-3" unitRef="USD">3502000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaid contextRef="D230101_230930" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="D220101_220930" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:SharesOutstanding
      contextRef="E23Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3629000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">432000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-10986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">132279000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E23Q2" decimals="-3" unitRef="USD">121762000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y23Q3" decimals="-3" unitRef="USD">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">53000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y23Q3" decimals="-3" unitRef="USD">53000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-1012000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y23Q3" decimals="-3" unitRef="USD">-1012000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1071000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y23Q3" decimals="-3" unitRef="USD">1071000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3935000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y23Q3" decimals="-3" unitRef="USD">3935000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3630000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-11999000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">135144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E23Q3" decimals="-3" unitRef="USD">123702000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3628000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-12039000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">126006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E22" decimals="-3" unitRef="USD">114254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D230101_230930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">117000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D230101_230930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D230101_230930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D230101_230930" decimals="-3" unitRef="USD">117000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D230101_230930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">153000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D230101_230930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D230101_230930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="D230101_230930" decimals="-3" unitRef="USD">153000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D230101_230930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D230101_230930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">41000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D230101_230930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D230101_230930" decimals="-3" unitRef="USD">41000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D230101_230930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D230101_230930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D230101_230930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3212000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="D230101_230930" decimals="-3" unitRef="USD">3212000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D230101_230930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D230101_230930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D230101_230930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D230101_230930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">12349000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D230101_230930" decimals="-3" unitRef="USD">12349000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3630000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-11999000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">135144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E23Q3" decimals="-3" unitRef="USD">123702000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3625000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-11858000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">119293000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E22Q2" decimals="-3" unitRef="USD">107471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y22Q3" decimals="-3" unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">38000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y22Q3" decimals="-3" unitRef="USD">38000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-2572000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y22Q3" decimals="-3" unitRef="USD">-2572000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1051000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y22Q3" decimals="-3" unitRef="USD">1051000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">4280000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q3" decimals="-3" unitRef="USD">4280000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3625000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">58000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-14431000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">122521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E22Q3" decimals="-3" unitRef="USD">108185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E21_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3655000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-9054000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">115314000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E21" decimals="-3" unitRef="USD">107138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D220101_220930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D220101_220930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D220101_220930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D220101_220930" decimals="-3" unitRef="USD">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D220101_220930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">121000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D220101_220930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D220101_220930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="D220101_220930" decimals="-3" unitRef="USD">121000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">-30000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D220101_220930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">-947000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D220101_220930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D220101_220930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">-1548000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="D220101_220930" decimals="-3" unitRef="USD">-2495000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D220101_220930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D220101_220930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-5377000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D220101_220930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D220101_220930" decimals="-3" unitRef="USD">-5377000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D220101_220930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D220101_220930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D220101_220930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3162000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="D220101_220930" decimals="-3" unitRef="USD">3162000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D220101_220930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D220101_220930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D220101_220930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D220101_220930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">11918000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D220101_220930" decimals="-3" unitRef="USD">11918000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3625000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">58000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-14431000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">122521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E22Q3" decimals="-3" unitRef="USD">108185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2022. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
 &lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;(3) Inventories at September 30, 2023, and December 31, 2022, consisted of the following:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:411.4pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; September 30, 2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,338&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,896&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,654&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,193&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,717&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,725&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,709&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,814&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D230101_230930">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:411.4pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; September 30, 2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,338&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,896&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,654&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,193&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,717&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,725&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,709&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,814&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E23Q3" decimals="-3" unitRef="USD">2338000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E22" decimals="-3" unitRef="USD">1896000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess contextRef="E23Q3" decimals="-3" unitRef="USD">1654000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E22" decimals="-3" unitRef="USD">1193000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials contextRef="E23Q3" decimals="-3" unitRef="USD">5717000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E22" decimals="-3" unitRef="USD">5725000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet contextRef="E23Q3" decimals="-3" unitRef="USD">9709000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E22" decimals="-3" unitRef="USD">8814000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(4) Stock-Based Compensation. At September 30, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2023, and 2022, the Company recognized $53 and $38, respectively, in stock based compensation cost. &#160;In the nine months ended September 30, 2023, and 2022, the Company recognized $153 and $121, respectively, in stock based compensation cost.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y23Q3" decimals="-3" unitRef="USD">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y22Q3" decimals="-3" unitRef="USD">38000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D230101_230930" decimals="-3" unitRef="USD">153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D220101_220930" decimals="-3" unitRef="USD">121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(5) Warranty Reserve. &#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022, or September 30, 2023. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="E22" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="E23Q3" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) Global 3Q 2023 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,066&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;357&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,423&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,600&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,772&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,372&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,363&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;521&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,884&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,236&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,590&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,826&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total:&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,265&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,240&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,505&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 9M 2023 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,725&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;788&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,513&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,805&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,076&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;16,881&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,892&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,150&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,042&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,045&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,410&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,455&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total:&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;21,467&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;16,424&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;37,891&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleOfRevenuesByProductCategoryTextBlock contextRef="D230101_230930">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,066&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;357&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,423&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,600&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,772&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,372&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,363&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;521&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,884&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,236&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,590&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,826&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total:&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,265&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,240&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,505&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 9M 2023 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,725&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;788&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,513&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,805&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,076&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;16,881&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,892&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,150&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,042&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,045&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,410&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,455&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total:&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;21,467&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;16,424&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;37,891&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</fil:ScheduleOfRevenuesByProductCategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">357000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-Obstetrics"
      decimals="-3"
      unitRef="USD">1423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">2772000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      unitRef="USD">5372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1363000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">521000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-Neonatal"
      decimals="-3"
      unitRef="USD">1884000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">1590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      unitRef="USD">3826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">7265000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q3_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">5240000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y23Q3" decimals="-3" unitRef="USD">12505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">788000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-Obstetrics"
      decimals="-3"
      unitRef="USD">3513000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">7805000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">9076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      unitRef="USD">16881000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">3892000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">1150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-Neonatal"
      decimals="-3"
      unitRef="USD">5042000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">7045000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">5410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      unitRef="USD">12455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">21467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230930_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">16424000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D230101_230930" decimals="-3" unitRef="USD">37891000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="D230101_230930">&lt;p style="font:12pt Times New Roman;margin:0;color:#000000"&gt;&lt;span style="font-size:10pt"&gt;(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) as of February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;amp;A expenses over a remaining one month of life as of September 30, 2023 of the prior CSI distribution agreement with Femcare Ltd.&lt;/span&gt;&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="-3"
      unitRef="USD">21000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <fil:RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem
      contextRef="D230930_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="0"
      unitRef="Pure">1</fil:RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem>
    <us-gaap:EarningsPerShareTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3rd quarter 2023.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Nine months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,935&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,280&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,349&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,918&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,629&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,625&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,629&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,641&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,639&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,634&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,638&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,650&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.08&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.18&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.40&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.27&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.08&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.18&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.39&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.26&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Nine months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:337.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:391.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,935&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,280&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,349&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,918&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,629&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,625&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,629&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,641&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,639&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,634&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,638&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,650&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.08&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.18&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.40&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.27&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:321.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:136.85pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.08&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:39.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:161.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.18&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:45.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:184.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.39&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:34.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:172.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.26&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="Y23Q3" decimals="-3" unitRef="USD">3935000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q3" decimals="-3" unitRef="USD">4280000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D230101_230930" decimals="-3" unitRef="USD">12349000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D220101_220930" decimals="-3" unitRef="USD">11918000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y23Q3" decimals="-3" unitRef="Shares">3629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y22Q3" decimals="-3" unitRef="Shares">3625000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D230101_230930" decimals="-3" unitRef="Shares">3629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D220101_220930" decimals="-3" unitRef="Shares">3641000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y23Q3" decimals="-3" unitRef="Shares">10000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y22Q3" decimals="-3" unitRef="Shares">9000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D230101_230930" decimals="-3" unitRef="Shares">9000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D220101_220930" decimals="-3" unitRef="Shares">9000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y23Q3" decimals="-3" unitRef="Shares">3639000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y22Q3" decimals="-3" unitRef="Shares">3634000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D230101_230930" decimals="-3" unitRef="Shares">3638000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D220101_220930" decimals="-3" unitRef="Shares">3650000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic contextRef="Y23Q3" decimals="INF" unitRef="UsdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y22Q3" decimals="INF" unitRef="UsdPerShare">1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D230101_230930"
      decimals="INF"
      unitRef="UsdPerShare">3.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D220101_220930"
      decimals="INF"
      unitRef="UsdPerShare">3.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y23Q3" decimals="INF" unitRef="UsdPerShare">1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y22Q3" decimals="INF" unitRef="UsdPerShare">1.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D230101_230930"
      decimals="INF"
      unitRef="UsdPerShare">3.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D220101_220930"
      decimals="INF"
      unitRef="UsdPerShare">3.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock contextRef="D230101_230930">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(9) Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-#+"6K6Y/(7;L2N[8\,.I;*J:O(A@FRX!!AAL?H\GL+MV)7=L6&_<C2,0%X
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M<\B5'Z_T4_2%[20(B!6>C[?[L>@HW[5<TJ .2#H-26>0Y#2*> ZT:J)<K9F
M]A&Q>$OO$R9/4,:4B7/EUMUC8SN!WZ&L@US7#LR,W8:Q.\AX ;G,%!<Q,^;2
MU5X9^EHJ=5 08,?,RVMX>8.\KLK414?KV]/>[3BDPT_'N-@UT_,;>OX@O5NN
M:/(*>K[V:FSAP.E^61T6A"$.S1R#AF,PR/%:@'P*]8R@U2'V(X\WQ9+I+<'
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MFB;X&02A'7!_S;G:&[K3MA]6_R]02P,$%     @ +U9M5WL3<*SP!0  FAH
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MTWA!BQ(@WR\9$V\W90/MYZC)WU!+ P04    "  O5FU73"?+(;T"   L"
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MFZT'RQG,XG3U._J\#F)K .4[!K#U *8-8+T= _AZ -<'T!T#W/4 5Y]2?\<
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M[I!K=R/9VIP3S9F4+#&7*X(7A&L!]?N2,;F_T2_(CQK[_P%02P,$%     @
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MY":*!)5Z0%@C.N!0&A78SDA;E#YHMD:NO%A!9"+C*(8VM0U!]"#U#Y/QBW]
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M!L%"80VW Y!TJY2B<@SHI%!T27V#@PUOO,08O('W924+P5?2,P!6%;D 7=!
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ML^GY60*N?Z[Z2;!-?"*V-M"#$X<UO?#HV(#V*TL]=)AP@/$_P_H?4$L#!!0
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MSH'.MXK>]M%P"4Z_L^4_4$L#!!0    ( "]6;5?P"72M]@(  'D&   9
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MGKAH@P/?5T3^8(0 XPPO_@%02P,$%     @ +U9M5P"FN%EE @  504  !D
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M-:ZI>N3-'71^(L.7<2KM%S5M['CJH*R6BI<=6"LH"6O_^+U;ASV /_H"$'2
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M4I+#EC<"5ZK]";V?.Z>7*6'\E[1=[N2>DJPQJ*H>MA54I>Q:?NCWX0083RX
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MT*IN(._?,R:>3VJ";O_V^G]02P,$%     @ +U9M5T]>$V>E @  ! 8  !D
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MV"Y@O0/QW7&@I]P^402[BFG#GF <21(,@5YT]V@<(]6)X>/>'^PIB:(D<2.
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MF><CK)O+6\6SP[>-PW>9ZU]02P,$%     @ +U9M5__DO>-" 0  11   !H
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MO?F=>CO_:(R;>YYK//^=5/OQ63,?/RV?FXMW?,)9PU^#TR]02P,$%     @
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M@S_K?I#,/@%02P$"% ,4    "  O5FU7!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "]6;5>N]](N
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( "]6;5>97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ +U9M5^,$J,C.!0  SAX
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M965T-2YX;6Q02P$"% ,4    "  O5FU7+T"6.QH(  #Z/   &
M    @($'(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M+U9M5R"%&*O?!@  =AP  !@              ("!5R@  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( "]6;5=JN1AO<P,  (,'   8
M          " @6PO  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  O5FU7K-=PLY$"  #8!0  &               @($5,P  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ +U9M5UTU[LEE @  4@4
M !D              ("!W#4  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  O5FU7=!?%^Y "  #3!0  &0              @(%X.
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "]6;5>$G1D_
MS ,  #\(   9              " @3\[  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ +U9M5W2*39(( P  V@8  !D
M ("!0C\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  O
M5FU7\ ETK?8"  !Y!@  &0              @(&!0@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( "]6;5?M#L<_; ,  /<'   9
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M970Q.2YX;6Q02P$"% ,4    "  O5FU7*D"X-00#  #Q!@  &0
M    @($^5   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M "]6;5<0?KS0@P(  ,(&   9              " @7E7  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ +U9M5XC.,I*' @  O0<  !D
M             ("!,UH  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  O5FU7$R3I:Q,"  #J!   &0              @('Q7   >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "]6;5>6F@'5WP4
M ,LM   9              " @3M?  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ +U9M5T]>$V>E @  ! 8  !D              ("!
M464  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  O5FU7
MC\ZQE'L#  "C#   &0              @($M:   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( "]6;5>]O@E*_P(  (D/   -
M      "  =]K  !X;"]S='EL97,N>&UL4$L! A0#%     @ +U9M5Y>*NQS
M    $P(   L              ( !"6\  %]R96QS+RYR96QS4$L! A0#%
M  @ +U9M5^:J=QSH @  &Q(   \              ( !\F\  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( "]6;5?_Y+WC0@$  $40   :
M  "  0=S  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M "]6;5>J'1"P=@$  "@1   3              "  8%T  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     B "( )0D  "AV      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>81</ContextCount>
  <ElementCount>131</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve</Role>
      <ShortName>Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - Warranty Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails</Role>
      <ShortName>Warranty Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="utmd-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="utmd-20230930.htm">utmd-20230930.htm</File>
    <File>utmd-20230930.xsd</File>
    <File>utmd-20230930_cal.xml</File>
    <File>utmd-20230930_def.xml</File>
    <File>utmd-20230930_lab.xml</File>
    <File>utmd-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="441">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>43
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20230930.htm": {
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "utmd-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "utmd-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 129,
   "keyCustom": 2,
   "axisStandard": 3,
   "axisCustom": 1,
   "memberStandard": 4,
   "memberCustom": 7,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 81,
   "entityCount": 1,
   "segmentCount": 11,
   "elementCount": 179,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 441,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "E21_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E21_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation",
     "longName": "000080 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples",
     "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureInventories",
     "longName": "000100 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation",
     "longName": "000110 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve",
     "longName": "000120 - Disclosure - Warranty Reserve",
     "shortName": "Warranty Reserve",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition",
     "longName": "000130 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure",
     "longName": "000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure",
     "shortName": "CSI Distribution Agreement Purchase Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare",
     "longName": "000150 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents",
     "longName": "000160 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies",
     "longName": "000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables",
     "longName": "000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)",
     "shortName": "Inventories: Schedule of Inventory, Current (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables",
     "longName": "000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables",
     "longName": "000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D230101_230930",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
     "longName": "000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)",
     "shortName": "Inventories: Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails",
     "longName": "000220 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails",
     "longName": "000230 - Disclosure - Warranty Reserve (Details)",
     "shortName": "Warranty Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E23Q3",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
     "longName": "000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y23Q3_ProductOrService-Obstetrics",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
     "longName": "000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)",
     "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "longName": "000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y23Q3",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20230930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r55",
      "r252",
      "r269",
      "r273",
      "r277",
      "r293",
      "r363"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r79",
      "r93",
      "r143",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r199",
      "r203",
      "r219",
      "r363",
      "r400",
      "r401",
      "r406"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r150",
      "r244",
      "r357",
      "r363",
      "r396",
      "r397"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r243"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r15",
      "r55"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r93",
      "r125",
      "r130",
      "r134",
      "r136",
      "r143",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r219",
      "r356",
      "r400"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r34",
      "r55"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r347",
      "r353"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r185"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {2}",
        "terseLabel": "Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income",
        "totalLabel": "Operating income",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130",
      "r134",
      "r136",
      "r356"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r80",
      "r82",
      "r90",
      "r93",
      "r99",
      "r109",
      "r110",
      "r125",
      "r130",
      "r134",
      "r136",
      "r143",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r198",
      "r201",
      "r202",
      "r215",
      "r219",
      "r247",
      "r256",
      "r279",
      "r312",
      "r327",
      "r328",
      "r356",
      "r361",
      "r362",
      "r373",
      "r386",
      "r400"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r120",
      "r121",
      "r122"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r67",
      "r68",
      "r85",
      "r94",
      "r95",
      "r96",
      "r100",
      "r108",
      "r144",
      "r147",
      "r172",
      "r182",
      "r183",
      "r184",
      "r190",
      "r191",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r213",
      "r225",
      "r226",
      "r231",
      "r235",
      "r267",
      "r268",
      "r278",
      "r294",
      "r310",
      "r330",
      "r331",
      "r336",
      "r373",
      "r389",
      "r395",
      "r405",
      "r411"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r43",
      "r60",
      "r125",
      "r130",
      "r134",
      "r136",
      "r247",
      "r255",
      "r356"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r83",
      "r87",
      "r245",
      "r257"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r34",
      "r55",
      "r177"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r186",
      "r408"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired, shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r34",
      "r55"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r239"
     ]
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit attributable to exercise of stock options",
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r65",
      "r109",
      "r110",
      "r128",
      "r189",
      "r195",
      "r259"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r57",
      "r274",
      "r275"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Right of Use Assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per common share (basic)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r123",
      "r214",
      "r215",
      "r246",
      "r258",
      "r354"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r93",
      "r143",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r200",
      "r203",
      "r204",
      "r219",
      "r363",
      "r400",
      "r406",
      "r407"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r124",
      "r239",
      "r276",
      "r281",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r368"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r93",
      "r143",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r200",
      "r203",
      "r204",
      "r219",
      "r291",
      "r355",
      "r374",
      "r400",
      "r406",
      "r407"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r76",
      "r93",
      "r125",
      "r131",
      "r135",
      "r143",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r199",
      "r203",
      "r219",
      "r249",
      "r304",
      "r363",
      "r374",
      "r400",
      "r401",
      "r406"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock - options",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements and Changes in Accounting Principles",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r66",
      "r69",
      "r97",
      "r98",
      "r101",
      "r102",
      "r111",
      "r112",
      "r145",
      "r146",
      "r192",
      "r193",
      "r194",
      "r210",
      "r212",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r232",
      "r233",
      "r236",
      "r240",
      "r241",
      "r242",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r391",
      "r392",
      "r404",
      "r410",
      "r411"
     ]
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TableTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r59",
      "r253",
      "r363",
      "r389",
      "r395",
      "r405"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r37",
      "r38",
      "r52",
      "r294",
      "r310",
      "r330",
      "r331",
      "r363",
      "r374",
      "r389",
      "r395",
      "r405",
      "r411"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {1}",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r239",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r348",
      "r358",
      "r364",
      "r383",
      "r398",
      "r399",
      "r402",
      "r409"
     ]
    },
    "fil_DomesticUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "DomesticUsMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DomesticUsMember",
        "documentation": "Represents the DomesticUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r20"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r239",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r348",
      "r358",
      "r364",
      "r383",
      "r398",
      "r399",
      "r402",
      "r409"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash &amp; investments",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r73",
      "r350"
     ]
    },
    "fil_ObstetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "ObstetricsMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obstetrics",
        "documentation": "Represents the Obstetrics, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "fil_OutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "OutsideUsMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OutsideUsMember",
        "documentation": "Represents the OutsideUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "fil_DistributionRightsAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "DistributionRightsAcquisitionAxis",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Rights Acquisition [Axis]",
        "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "fil_NeonatalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "NeonatalMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neonatal",
        "documentation": "Represents the Neonatal, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blood Pressure Monitoring and Accessories",
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "fil_CoopersurgicalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "CoopersurgicalIncMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CooperSurgical Inc",
        "documentation": "Represents the CooperSurgical Inc, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increase in cash and cash equivalents",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r49"
     ]
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gynecology/Electrosurgery/Urology",
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "negatedLabel": "Intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "fil_ScheduleOfRevenuesByProductCategoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "ScheduleOfRevenuesByProductCategoryTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenues By Product Category",
        "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash at beginning of period",
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r49",
      "r92"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r282",
      "r283",
      "r284",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r359",
      "r367",
      "r402",
      "r409"
     ]
    },
    "fil_DistributionRightsAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "DistributionRightsAcquisitionDomain",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Rights Acquisition",
        "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r124",
      "r239",
      "r276",
      "r281",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r368"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r352"
     ]
    },
    "fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System",
        "documentation": "Represents the Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r250"
     ]
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options, shares",
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, diluted",
        "verboseLabel": "Earnings per common share (diluted)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r116",
      "r117",
      "r118",
      "r119",
      "r123",
      "r214",
      "r215",
      "r246",
      "r258",
      "r354"
     ]
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20230930",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options",
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r282",
      "r283",
      "r284",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r359",
      "r367",
      "r402",
      "r409"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts &amp; other receivables, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option compensation expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted shares",
        "verboseLabel": "Shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r119"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of stock options",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating expense",
        "totalLabel": "Total operating expense",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r363"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization {1}",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22",
      "r24"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSI Distribution Agreement Purchase Disclosure",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r158",
      "r161",
      "r162"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r280",
      "r391",
      "r392",
      "r393",
      "r404",
      "r411"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares, basic",
        "verboseLabel": "Shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r119"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r129",
      "r132",
      "r133",
      "r137",
      "r138",
      "r140",
      "r173",
      "r174",
      "r239"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r179",
      "r180",
      "r181",
      "r360"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r223",
      "r230"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability - Femcare IIA",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r403"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductWarrantyDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureWarrantyReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranty Reserve",
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2023, 3,629 shares and December 31, 2022, 3,628 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r251",
      "r363"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r292"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r15",
      "r67",
      "r84",
      "r85",
      "r86",
      "r94",
      "r95",
      "r96",
      "r100",
      "r108",
      "r110",
      "r124",
      "r144",
      "r147",
      "r172",
      "r182",
      "r183",
      "r184",
      "r190",
      "r191",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r213",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r235",
      "r266",
      "r267",
      "r268",
      "r280",
      "r329"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r292",
      "r310",
      "r411",
      "r412"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "totalLabel": "Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r351",
      "r363"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r94",
      "r95",
      "r96",
      "r100",
      "r108",
      "r110",
      "r144",
      "r147",
      "r182",
      "r183",
      "r184",
      "r190",
      "r191",
      "r205",
      "r207",
      "r208",
      "r211",
      "r213",
      "r266",
      "r268",
      "r280",
      "r411"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r56",
      "r62",
      "r196",
      "r197",
      "r390"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r248",
      "r254",
      "r363"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r153"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r84",
      "r85",
      "r86",
      "r94",
      "r95",
      "r96",
      "r100",
      "r108",
      "r110",
      "r124",
      "r144",
      "r147",
      "r172",
      "r182",
      "r183",
      "r184",
      "r190",
      "r191",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r213",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r235",
      "r266",
      "r267",
      "r268",
      "r280",
      "r329"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total adjustments",
        "totalLabel": "Total adjustments",
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r363"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for (recovery of) losses on accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r148"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.utahmed.com/20230930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001811884-23-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001811884-23-000021-xbrl.zip
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MNW6^G$>K2ZWOVH 6'ONV0QU+&_!"BE4( U28@YH],KAY\CNPSZMDBH <&9"
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M0-UX]G--J.R6\ME2PSP3+(J]V!"J4ER>L/.0T#E@Z0.6<OY,US$'WT:F#H(
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MX)]8(BC.D^QZE9@,^Y!B3?$YBM#_4/0IC8S.<;<BXI.JL02PTR!JQ.>OT#Z
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MZ1C? =VF-4M,1[H10[".O5\]RZ:*)Y5+^8KX$&GP[J8D15E@8F1-& O$DY1
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M/<>FA'E2"P>NC\QZ@-GA8Q_7K-32XNGF2_?ZX7\8 I:VAY\4\??UC>+V8]B
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M%XV>LG$=CX@?[^[[O$/# %;Y:F)8\\9;R.O,H&BNOLZN"=6!#!9>=GREUDP
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MCD*.-=G661<5M'H=N!>SJ$F7;KL@G\9+Y!T(WO4A.SOUWOFV[Z]@#1^1A&N
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MCT30EQY^C,7!;Q128Z5 8F(XS1L=J,(5B=CA^QE*#5F3G_VIPLV*8GR6BX#
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MU6I,-GUMKT;1(_Z#)8+PWW$QB7_[/_\?4$L#!!0    ( "]6;5</]&F@6@@
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M4<S$ANK.GHU.L_!PG=(30\3W[%QAR7 &U*LOZJ7*OO#(GC*X+[(^1^B7S&=
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MO\!"HOG"I\6$=WSTK7TQRJB)YW-6?@EYV?JIWWV7I;RMT^Y<^"]<?--;<IA
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MTO+I^&XB(<B,\<ZB\^KJ:9O%_.7"[5=T:V\1M5;@;8Q@1_;4)N!&LNH_^G\
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MV&3WH.IMMG]X&="JMY:A6I_5VF01ZP ),_,O309,5K^*WYAH[A6V!\^[,DE
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M-9'\0FL;F6U53R7ZSR.]G$0N:/G#P!8P2%4M3Q/PPT?];=R';8C=*(@6VU&
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M-;_!)6J7\T)RD25JK6?)$DH!@8UR:I.#A";DSY./([U5E: :ZLK_6Z.HY5F
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MFA6OO$O*K6_PL3QC+]D,U[?5\Y0ND "T6[ YDU^CUO6/V$V&[S&?WZ6?N$[
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MFA=-XS-PO&.6V%C%1<4F(G]!:2?U[@E&WXO5_,#V+?5Y@56XZ_0!8V_[=GN
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M3]]_EO^&_+][<G#]_K/_ U!+ P04    "  O5FU7X0V :N<7  "]@0$ %0
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M<D(G7154A#ZUXH9#KS85H:"'('0UO7;B.W6;5XK?&PYRR1@$U1ZWS:YWY9W
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M>0FA1IS!#Z^\A1S@X+Y*6<3.X9D:!8-<VT?&O'OJEY,F*U_;2</:.H-\&5A
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M)J]AM\Q;NN.KK2,NN][N7G%U-5OCN#J!4;U#S#0O54UCZM=)U3S?9!]5H^Z
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MEF6\QXJM/S@ /S=R6RM'[I ;Q N12<;L*E6C&%0$IG,!+,,6*KB:*LL"&.>
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M@^?TM@&Z-!TSRT,IV__,E @P0AK?DBX-1W,K[$&+SF!IL;+KP%DUY7I5%(D
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M+ "EBQ6H!J[2.6TU^GZ%2_DUJ^:^OOT#4$L#!!0    ( "]6;5=M<JV4500
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M3>O))CASU T@QV, *D7@D0VY2LM"9FA!:"2:<@1"=1C_V7J1/84^L'C'V)#
MXE<0BZBP4TF!SUQC8]78#;%11%LSMX_;!6N6T[*#F)YI]&.B(;I0U'8%(%)2
M/']:'6\D;FU$;MVQ4C9-,1 E.(O@EJJR8WXS@17VJY#B*ZG$+8L1KFHZE6JM
MNM<,'2$TSEMY"&;[=$Y2*,[RU3W OVGD"AAZ.$:3)%!(?&/XQ&[G=6JC[B.Y
MU,Q9&B_5R;I6_B?P#U!+ 0(4 Q0    ( "]6;5=6.6N5?*@   %W"  1
M          "  0    !U=&UD+3(P,C,P.3,P+FAT;5!+ 0(4 Q0    ( "]6
M;5</]&F@6@@  %=$   1              "  :NH  !U=&UD+3(P,C,P.3,P
M+GAS9%!+ 0(4 Q0    ( "]6;5?388O I@D  /%[   5              "
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M! $ =71M9%]E>#,Q>C$N:'1M4$L! A0#%     @ +U9M5UQ*[Z/R!@  A1L
M  \              ( !Y0L! '5T;61?97@S,7HR+FAT;5!+ 0(4 Q0    (
M "]6;5=M<JV4500  "@,   /              "  003 0!U=&UD7V5X,S)Z
M,2YH=&U02P$"% ,4    "  O5FU7R[7K5#T$   1#   #P
K@ &&%P$ =71M9%]E>#,R>C(N:'1M4$L%!@     *  H ?@(  / ; 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
